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ABSTRACT 
Background: Rheumatoid Arthritis (RA) is an autoimmune disease, which is treated with 
anti-inflammatory and immunosuppressive medication. The aim of the treatment is 
clinical remission. Starting from late 1990’s biologic disease-modifying anti-rheumatic 
drugs (bDMARDs) have been used to treat patients with insufficient treatment response 
or intolerance to synthetic DMARDs (sDMARDs).  Despite numerous randomized clinical 
trials (RCTs) conducted so far, only few studies comparing biologic drugs to one another 
exist. Furthermore, the patients eligible for RCTs may not fully represent the population 
exposed to biologics in routine healthcare. Additionally, some clinical outcomes or 
adverse effects may be too rare or delayed to be studied in an experimental RCT setting. 
Finally, there is limited information on the utilization of biologic treatments available in 
Finland.  
Objectives: The objective of the thesis was to study the efficacy, clinical outcomes and 
adverse events of the biologic drugs in treatment of rheumatoid arthritis.  
Methods: All published randomized controlled trials studying the efficacy and safety of 
biologic drugs based on the inhibition of tumor necrosis factor (TNF) were identified, 
evaluated and pooled in using a systematic review including a meta-analysis. Then we 
pursued a cross-sectional overview on the disease activity and medical treatment of 
patients with RA treated in the Finnish specialized healthcare.  Finally, we executed two 
cohort studies in which we combined longitudinal patient data with information on the 
incidence of serious infections, malignancies and joint replacement operations retrieved 
from national registers.  
Results: Forty-one articles reporting on 26 RCTs of TNF-inhibitors were included in the 
systematic review and meta-analysis. Five RCTs studied infliximab, seven etanercept, 
eight adalimumab, three golimumab and three certolizumab pegol. TNF-inhibitors as a 
monotherapy were more efficacious than placebo at all time points but were comparable 
to methotrexate (MTX). TNF-inhibitor and MTX combination was superior to either MTX 
or TNF-inhibitor alone. Increasing doses did not improve the efficacy. TNF-inhibitors were 
relatively safe compared to either MTX or placebo. The cross-sectional study revealed 
91% of patients as concurrent users of synthetic disease-modifying anti-rheumatic drugs 
(sDMARDs). A triple therapy of MTX, hydroxychloroquine (HCQ), and sulfasalazine (SSZ) 
was used by 15%, other MTX-based combination by 30%, MTX alone by 20%, and other 
DMARDs alone or in combination by 26% of patients. In addition, glucocorticoids and 
biologics were used by 58% and 21% of patients, respectively. Of the 184 biologics users, 
18% were not using sDMARDs concomitantly.  The adjusted incidence rate ratios (aIRRs) 
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of infections compared to sDMARD users were 1.2 (95% CI 0.63-2.3), 0.84 (95% CI 0.53-
1.3), 0.98 (95% CI 0.60-1.6) and 1.1 (95% CI 0.59-1.9) for the users of infliximab, 
etanercept, adalimumab and rituximab, respectively. The crude rates of malignancies 
were highest among the users of sDMARDs and rituximab and lowest among infliximab-
treated patients with no differences in aIRRs. There were more primary joint replacement 
operations per 100 patient years among the users of biologic drugs (3.89, 95% CI 3.41–
4.41) vs. DMARD (2.63, 2.35–2.94) users but slightly fewer revisions (0.65, 0.46–0.88 vs. 
0.83, 0.68–1.01). Biologics users were more likely to receive a joint replacement to small 
joints (p < 0.001). The survival of the prostheses installed during or prior to follow-up was 
similar in both treatment groups. 
Conclusions: Pooled data from RCTs showed that the safety of TNF-inhibitors is 
comparable to sDMARDs and only few differences were observed between individual 
agents. TNF-inhibitors are more efficacious in combination with MTX when compared 
against monotherapy with either TNF-inhibitors or MTX alone. Currently, more than 20% 
of Finnish RA patients are using biologic drugs, with a majority of them in combination 
therapy with sDMARDs. The incidence of serious infections and malignancies is 
comparable between the users of sDMARDs, TNF-inhibitors and rituximab. Compared to 
sDMARD users, bDMARD users had a higher incidence of joint replacement operations 
while the durability of the prostheses and the incidence of post-operational infections 
were similar. 
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1 INTRODUCTION 
Rheumatoid Arthritis (RA) is an autoimmune disease with a prevalence of 0.8 per cent in 
Finland [1,2]. Symptoms comprise polyarticular joint tenderness and swelling especially in 
hands and feet, resulting in impaired mobility, bone erosions and progressive joint 
destruction due to the synovial inflammatory process [3]. Women are affected more 
often than men and typically first symptoms arise in persons over 50 years of age, two-
thirds of whom are at working age at the time of diagnosis [2,4]. Currently diagnosis of 
disease relies on the ACR/EULAR classification criteria of 2010 that may help identifying 
patients that are most likely to benefit from early initiation of therapy [5]. Several clinical, 
laboratory and patient self-reported measures are being used to quantify the severity of 
RA such as the number of swollen and tender joints, C-reactive protein (CRP) level and 
health assessment questionnaire (HAQ).   
Treatment of RA is focused on reducing the inflammatory process and retaining the 
patients’ physical ability always aiming at remission or low disease activity using a treat-
to-target approach [6,7]. European guidelines suggest starting Disease Modifying Anti-
Rheumatic Drug (DMARD) therapy using a synthetic DMARD (sDMARD) strategy in 
combination with glucocorticoids, followed by the addition of a biological DMARD 
(bDMARD) or another cDMARD strategy  if the treatment target is not reached within 6 
months (or improvement not seen at 3 months) [8]. In Finland, current care guidelines 
suggest that early RA should be treated with methotrexate (MTX) or in more severe cases 
with a combination of MTX, hydroxychloroquine, sulfasalazine and prednisolone [7,9].  
Synthetic DMARDs are small-molecule drugs, which have been used in treatment of 
inflammatory diseases for several decades and comprise drugs such as MTX, SSZ, HCQ, 
leflunomide and intra-muscular gold. The first biological drug was introduced to clinical 
use in 1999. Biological drugs are currently recommended for patients with insufficient 
treatment response or intolerance to sDMARDs including MTX [7]. In case of treatment 
failure with the first biological treatment, usually tumour necrosis factor (TNF)-inhibitors, 
any other biological drug may be considered. At the moment, nine different biological 
drugs (infliximab, etanercept, adalimumab, anakinra, rituximab, abatacept, tocilizumab, 
certolizumab pegol and golimumab) have been authorized for the treatment of RA in 
Europe [10]. In addition, two biosimilar alternatives for infliximab were authorized in 
2013. The number of patients using self-administered biologic drugs and the ensuing 
medication costs more than quadrupled between 2004 and 2012 ([11], personal 
communication Saastamoinen Leena/KELA September 2009). No information on the use 
of intravenously administered biologics is available from administrative databases. 
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Moreover, it is not known to what extent non-biologic sDMARDs are used concomitantly 
with biologic treatments. 
Majority of the information on the efficacy and safety of biologic treatments has been 
derived from randomized controlled trials (RCTs), which are required by the medicines 
agencies before a drug gains marketing authorization. While RCTs can provide high 
quality evidence their stringent inclusion criteria for patients and often brief follow-up 
times limit the generalizability of the results to routine care [12].  Observational trials 
based on either retrospective, administrative healthcare data or purpose-collected 
prospective data can provide results based on the true use of medicines among real 
patients [13]. Furthermore, observational trials often comprise large number of patients, 
enabling the researchers to study correlations between the use of medication and 
outcomes with low incidence. However, observational trials are prone to various types of 
biases, which reflect the lack of randomization and the quality and completeness of the 
data. 
RCTs have shown that biologic drugs in combination with sDMARDs reduce patients’ 
symptoms better than sDMARDs although the main active comparator used in most trials 
usually has only been methotrexate as monotherapy. In early disease, the few studies 
having featured a combination of sDMARDs as an active comparator, have demonstrated 
a more modest improvement in terms of efficacy, or none at all [14–16]. Nevertheless, 
initiating a TNF-inhibitor early in the course of the disease may help to inhibit or delay 
radiological progression compared to any non-biological treatment as also stated in 
current therapy guide lines. It is assumed that the delayed radiological progression 
decreases the need for joint replacement surgery. However, aside from reduced overall 
incidence of joint replacement operations among RA patients, little actual evidence is 
available to support that conclusion [17,18]. Only a handful of RCTs have compared 
biologic drugs to one another [19,20]. In the absence of more head-to-head studies, 
systematic reviews featuring a meta-analysis can provide some evidence on the 
comparative effectiveness and safety of individual biologic agents [21,22]. 
Numerous RCTs have shown that biologic drugs have a safety profile comparable to 
methotrexate with some differences, most notably the increased risk for tuberculosis 
reactivation [22,23]. Observational studies however, have identified an increased 
incidence for several types of infections and malignancies among users of TNF-inhibitors 
compared to sDMARD users although the evidence available thus far may be insufficient 
to conform the causality [24].   
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2 REVIEW OF THE LITERATURE 
2.1 Rheumatoid arthritis 
2.1.1 Incidence and prevalence 
Rheumatoid Arthritis (RA) is a chronic autoimmune disease, which is divided into 
seropositive and seronegative subtypes based on the presence of Rheumatoid Factor (RF) 
and Anti-Cyclic Citrullinated Peptide (Anti-CCP) [3]. Prevalence of RA in Northern Europe 
ranges from 0.5 to 1.0 per cent of the population while 0.8% of Finnish people have been 
diagnosed with RA [1,25]. The prevalence in the Northern America resembles that of 
Northern Europe although as much as six per cent of Native Americans may be affected 
whereas the prevalence is considerably lower in southern Europe and Asia. The annual 
incidence of RA in Finland has been estimated to be 26.7/100 000 persons and has been 
declining during the past decades [26]. The mean age at the diagnosis of RA is close to 60 
and it is more common among women compared to men [3,26].  
2.1.2 Symptoms 
The most important symptom of RA is joint inflammation, which causes tenderness and 
pain, morning stiffness and restriction of mobility [3]. The typical joint involvement early 
in the course of the disease is swelling of the proximal interphalangeal joints, the 
metacarpophalangeal joints, the wrists and the metatarsophalangeal joints.  Although the 
symptoms often arise from small and medium joints symmetrically on both sides, the 
disease can also start with monoarthritis, for example, of the knee and later develop into 
a more polyarticular, and classically symmetrical disease. The symptoms may also 
comprise fever and extra-articular manifestations such as pericarditis, pleuritis, sicca 
syndrome, nodules and interstitial lung fibrosis. Moreover, patient may feel fatigued.  
Over time, the chronic nature of RA may lead to physical disability. 
2.1.3 Diagnostic procedures 
RA is diagnosed by a combination of clinical findings and laboratory tests and several 
diagnostic criteria have been published, including the American College of Rheumatology 
(ACR) 1987 criteria [3,7,27]. Although the usefulness of the ACR 1987 criteria in clinical 
routine have been questioned, they are highly specific distinguishing RA from other 
rheumatic diseases in randomized clinical trials. Newer criteria, aiming specifically at 
identifying early RA were published in collaboration between the ACR and European 
League against Rheumatism (EULAR) in 2010 [5]. The ACR/EULAR 2010 criteria comprise 
four individually scored dimensions, namely joint involvement, serology, acute-phase 
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reactants and duration of symptoms (Table 1). Patients accumulating a total score of six 
or more out of ten are classifiable as having RA.   
 
Table 1. Scoring table for ACR/EULAR 2010 classification criteria for Rheumatoid Arthritis [5].  
Dimension Condition Score 
Joint involvement 1 large joint 0 
2-10 large joints 1 
1-3 small joints 2 
4-10 small joint 3 
>10 joints (at least one small joint) 5 
Serology Negative RF and negative anti-CCP 0 
Low positive RF or low positive anti-CCP 2 
High positive RF or high positive anti-CCP 3 
Acute phase reactants Normal CRP and normal ESR 0 
Abnormal CRP or abnormal ESR 1 
Duration of symptoms Less than 6 weeks 0 
More than 6 weeks 1 
RF=Rheumatoid factor; Anti-CCP= Anti-Cyclic Citrullinated Peptide; CRP=C-Reactive Protein; 
ESR=Erythrocyte Sedimentation Rate 
 
Typical findings of joint inflammation comprise soft tissue  swelling and tenderness, 
limited motion and synovitis [3,7]. Routine laboratory tests include C-reactive protein 
(CRP) concentration and erythrocyte sedimentation rate (ESR) as well as tests for RF and 
anti-CCP antibodies. Additionally, thrombocytosis, leukocytosis and reduced hemoglobin 
may also be present in active inflammatory disease. Furthermore, it is recommended to 
perform a general laboratory screening to examine any abnormalities in liver or kidney 
function. Imaging procedures typically used for RA patients comprise ultrasonography, x-
ray imaging and magnetic resonance imaging. Ultrasonography may be used to detect 
swelling of the synovial membrane, or synovitis of involved joints.  Also, a trained 
examiner can detect erosions of smaller joints at an early stage using ultrasound. While 
joint erosions examined using x-ray imaging is still the gold standard for diagnosing joint 
damage, the absence of erosions does not exclude the possibility of RA. The x-ray images 
of hand and feet are often evaluated at disease onset and subsequent evaluations at one 
and two years are used to assess disease progression [7].  
  
16 
2.1.4 Long-term outcomes 
Rheumatic joints may be eroded to a point that either the pain or limited mobility 
warrants replacing the joint with prosthesis. In 2011, more than 20,000 hip and knee total 
joint replacements were performed in Finland, which is nearly 80% increase from year 
2000 [28]. However, recent evidence suggests that the growth in the need for joint 
replacement operations is not due to RA, but osteoarthritis (OA) [29,30].   Estimated 25% 
of RA population will undergo a total hip replacement (THR) or a total knee replacement 
(TKR) operation within 21.8 years of the disease onset [31]. In addition, traditional 
rheumatic surgery comprises operations such as non-total joint replacement operations 
of minor joints and the removal of inflamed joint tissue (synovectomy). However, recent 
literature suggests that the need for rheumatic surgery, including  total joints 
replacements (TJR) has been on the decline during the past decade [17,18,32–35]. In 
California, the incidence rate of THR was reduced from 363 operations per 100,000 
person-years (CI 95% 352 to 375) in 1998-2002 to 324 (95% CI 313 to 334) in 2003-2007. 
Concomitantly, the rates of wrist and ankle operations decreased while the rates of TKR 
ascended [33]. Similarly in Sweden, the incidence rate of THR decreased from 12.6 
operations per 1,000 person-years in 1998-2001 to 4.8 in 2002-2006 while the rates of 
TKR slightly elevated [18]. 
Studies from different countries have shown that within three years of disease onset, up 
to 37% of previously employed patients with RA have become work disabled [36]. 
Although recent trends in Finland suggest a decreased incidence of work disability 
pension due to RA, the standardized incidence rate ratio is nevertheless three-fold 
compared to general population [37]. 
 
2.1.5 Pathogenesis of rheumatoid arthritis 
The pathogenesis of RA is complex, heterogeneous and to some extent, still unknown 
[38,39]. In essence, the body’s own defense mechanisms, which are programmed to 
defend the host from external threats, cause unintended excessive inflammation in the 
synovial joints. The immunological process that eventually leads to clinical symptoms is 
due to a complex interplay between the innate and adaptive immune systems, central 
nervous system and hypothalamus-pituitary-adrenal axis. Autoantigens and 
corresponding autoantibodies may be formed already in the subclinical phase of RA [40].  
Homozygotic twins have a higher risk for RA in comparison to heterozygotic twins given 
that the other twin already has been diagnosed with the disease and heritability is 
estimated to be 50-60% [41]. In addition to genetic factors, environmental factors such as 
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smoking, air pollutants, viral or bacterial agents and heavy coffee consumption may also 
predispose to rheumatoid arthritis [41–44]. Gonadal and adrenal hormones also play a 
role, which is highlighted by the sexual disparity in the incidence of RA and the fact that  
pregnancy may suppress the disease activity [45,46]. Progesterone and 17β-oestradiol at 
ovulatory to pregnancy levels stimulate B-cells while simultaneously inhibiting T-cells and 
macrophages and therefore women between puberty and menopause are more likely to 
suffer from B-cell driven RA rather than T-cell driven RA as is speculated to be the case 
with men and older women [38,46].  
Tissue damage is mediated through both innate and adaptive immune systems [38]. After 
being presented an antigen by professional antigen presenting cells, activated Th1 and 
Th17 helper T-cells migrate to the synovial  membrane to both inflict direct cellular 
damage through oxidative stress and to amplify the inflammatory reaction by means of 
releasing pro-inflammatory cytokines such as TNF, interleukin 1 (IL-1) and interleukin 6 
(IL-6), interleukin 17 (IL-17) as well as adhesion molecules, matrix metalloproteinases 
(MMPs) and also receptor activator of nuclear factor kappa-B ligand (RANKKL) [47] . Like 
T-cells, also B-cells are activated by contact with innate immune cells and contribute to 
the inflammatory process by producing antibodies such as RF and anti-CCP antibodies. Of 
the innate immunity cells, macrophages have a central role in the arthritic inflammation. 
Local synovial inflammation might lead to formation of citrullinated fibrinogen and 
thereafter, generation of anti CCP-antibodies and immune complexes, amplifying the 
synovitis process. The changes in the balance of the immune system lead to several 
interconnected pathophysiological consequences: synovial hyperplasia, angiogenesis, 
attraction and accumulation of immune cells to the synovium, spreading of inflamed 
synovial tissue and destruction of articular cartilage, bone and periarticular soft tissues 
and subsequently bone [39]. 
2.2 Measures of disease activity and treatment response in Rheumatoid Arthritis 
Disease-activity measures used in clinical trials of RA comprise a variety of different 
measures; clinical outcomes, laboratory tests and patient reported outcomes (PRO) 
typically reflecting the symptoms and clinical features of the condition [48]. The most 
frequently used clinical outcomes are the number of tender and swollen joints (TJC/SJC) 
based on scales typically measured using either 28 or 66/68 joint counts and the 
physicians evaluation of global disease activity [49–51]. Laboratory tests focus on acute-
phase reactants such as C-reactive protein (CRP) and erythrocyte sedimentation rate 
(ESR). Additionally, the PROs comprise a measure of physical function and the patients’ 
evaluation of global disease activity and pain, often using a visual analogue scale (VAS). 
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VAS usually features a 100mm horizontal line, where 0mm represents the minimal and 
100mm the maximal quantity of the symptom to be measured. Physical function is 
commonly evaluated using the Health Assessment Questionnaire Disability Index (HAQ-
DI), which is a modification from a more comprehensive questionnaire [52–54]. HAQ-DI 
comprises eight dimensions each with two or three questions. Answers to the questions 
are scored from 0 to 3, higher value signifying worse physical function. Additionally, the 
use of aids and devices as well as the need for outside help is inquired and used to adjust 
the score of related questions. Each dimension is assigned the highest score of its 
questions while the total HAQ-DI score is equal to the mean score of all dimensions. 
To simplify the interpretation of different individual disease activity measures various 
indices have been developed. Disease Activity Score based on the 28-joint count includes 
four variables, namely the number of tender and swollen joints, CRP or ESR and the 
patients global assessment of general health [49]. The formulae for DAS28 (ESR) and 
DAS28 (CRP) are presented in the Formula 1. Patient can be considered to be in the state 
of remission or low disease activity if the DAS28 score is lower than 2.6 or 3.2, 
respectively [50] (Table 1). A score between 3.2 and 5.1 signifies moderate disease 
activity while severe disease activity is defined as having a DAS28 greater than 5.1. Other 
indices comprise Simplified Disease Activity Index (SDAI) consisting of 28-joints counts, 
patient’s evaluation of general health, physician’s evaluation of general health and the 
CRP-level and Clinical Disease Activity Index (CDAI), which features same variables as the 
SDAI except the CRP [50,55,56]. The formulae for SDAI and CDAI are presented in Formula 
1. 
Formula 1. Formulae for disease activity indices  
  𝐷𝐴𝑆28 (𝐸𝑆𝑅) =  0.56 ∗ √𝑇𝐽𝐶28 + 0.28 ∗ √𝑆𝐽𝐶28 + 0.70 ∗ 𝐿𝑛(𝐸𝑆𝑅) + 0.014 ∗ 𝐺𝐻_1 
  𝐷𝐴𝑆28 (𝐶𝑅𝑃) = 0.56 ∗ √𝑇𝐽𝐶28 + 0.28 ∗ √𝑆𝐽𝐶28 + 0.36 ∗ 𝐿𝑛(𝐶𝑅𝑃_1 + 1) + 0.014 ∗ 𝐺𝐻_1
+ 0.96 
  𝑆𝐷𝐴𝐼 = 𝑆𝐽𝐶28 + 𝑇𝐽𝐶28 + 𝐺𝐻_2 + 𝑃𝐺𝐻 + 𝐶𝑅𝑃_2 
  𝐶𝐷𝐴𝐼 = 𝑆𝐽𝐶28 + 𝑇𝐶𝐽 + 𝐺𝐻_2 + 𝑃𝐺𝐻 
DAS28 = Disease Activity Index 28;  SDAI = Simplified Disease Activity Index; CDAI = Clinical Disease 
Activity Index; TJC = Tender Joint Count based on 28 joint count; SJC = Swollen Joint Count based on 
28 joint count; ESR = Erythrocyte Sedimentation Rate; GH_1= Patients assessment of general health 
on 0-100mm visual analoque scale; CRP_1 = C - reactive protein (mg/l); GH_2= Patients assessment 
of general health on 0-10 scale ; CRP_2 = C - reactive protein (mg/dl); PGH= Physicians assessment 
of general health on 0-10 scale 
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Table 1. Cut-off Values for DAS28, SDAI and CDAI composite measures 
Disease Activity DAS28 SDAI CDAI 
Severe/High >5.1 ≥26 ≥22 
Moderate ≤5.1 <26 <22 
Low <3.2 <11 <10 
Remission <2.6 ≤3.3 ≤2.8 
DAS28 = Disease Activity Index 28;  SDAI = Simplified Disease Activity Index; CDAI = Clinical Disease 
Activity Index; 
Treatment response can be presented either as the change in DAS28 or alternatively, 
using the EULAR treatment response criteria, which account for the magnitude of the 
change as well as the disease activity at baseline [57]. Alternatively, treatment response 
criteria by the American College of Rheumatology (ACR) are solely based on the relative 
change from the baseline [58]. The criteria for improvement are as follow: 20% 
improvement in tender and swollen joint counts and 20% improvement in 3 of the 5 
remaining ACR core set measures: patient and physician global assessments, pain, 
disability and an acute-phase reactant [48,58]. Similarly, as 20% improvement is required 
for ACR20 response, 50%, 70% and 90% improvements are required for ACR50, ACR70 
and ACR90 responses, respectively. 
Joint damage is typically assessed using a series of x-ray images of mainly hands and feet 
[50]. Scoring systems such as Larsen score and Sharp’s method have been developed and 
validated to assess the severity of erosions, but their use is limited mainly to randomized 
clinical trials. 
Several criteria for remission in RA have been developed. The remission criteria by ACR 
published in 1981 was very stringent and the authors described remission as the total 
absence of articular and extra-articular inflammation and immunologic activity related to 
RA [59]. Moreover, it included domains that are absent in the subsequent ‘core-set’ 
measures later defined by the ACR [48]. Subsequent introduction of composite measures 
such as DAS28 and its cut-off values representing remission proved themselves a valuable 
tool in clinical practice although there is some debate whether they are stringent enough 
[60,61]. In 2010, EULAR and ACR defined new criteria mainly to be used in clinical trials, 
which they described stringent but achievable [62]. The ACR/EULAR 2010 criteria feature 
two optional methods of defining remission, either a Boolean based definition or an 
index-based definition. The Boolean criteria require that the patient has no more than 
one tender and one swollen joint, CRP level no higher than one milligram per deciliter and 
the patients assessment of general health on 0-10 scale less or equal than one. 
Alternatively, the index-based definition is based on the SDAI requiring a composite score 
of less or equal than 3.3. 
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2.3 Treatment of Rheumatoid Arthritis 
2.3.1 Treatment recommendations  
Medical treatment of RA is aimed at reaching clinical remission, defined as the absence of 
clinical signs and symptoms of significant inflammatory disease activity [7,8]. 
Alternatively, among patients with long-standing disease, low disease activity may be a 
sufficient goal. Concurrent treatment strategy is known as Treat-to-Target approach 
where composite measures of disease activity are used on follow-up visits taking place 
every 1-3 months during active disease and treatment is adjusted at least every 3 months 
until the treatment aim is achieved [8].  
Following a clinical diagnosis of RA, EULAR recommends starting the treatment with MTX 
or with a combination of synthetic DMARDs typically comprising MTX, SSZ and HCQ [8]. If 
the treatment target is not reached, and poor prognostic factors are present (presence of 
autoantibodies RF or ACPA; high disease activity measured by composite indices) addition 
of a bDMARD should be considered. Otherwise in the case of insufficient treatment 
response or contraindication to MTX, leflunomide or its combination with SSZ can be 
used. The first biologic is recommended to be a TNF-inhibitor, abatacept, tocilizumab or 
in certain conditions, rituximab. Should the treatment with first biologic be discontinued 
owing to lack of effectiveness or toxicity a second biologic, preferably abatacept, 
rituximab, tocilizumab or a second TNF-inhibitor should be commenced. The EULAR 
recommendation also includes the JAK-inhibitor tofacitinib even though it has not been 
authorized by EMA for treatment of RA. 
According to the Finnish  current care guidelines, treatment of RA should commence with 
MTX and in severe cases with the combination of MTX, SSZ HCQ and low-dose 
prednisolone, the so-called RACo combination [7]. In case of insufficient treatment 
response or intolerance to the synthetic disease modifying anti-rheumatic drugs 
(sDMARDs), biologic drugs, primarily TNF-inhibitors may be commenced. Should the 
treatment with TNF-inhibitors be unsuccessful, other biologics may be considered. The 
Finnish recommendations differ somewhat from the EULAR and ACR recommendations 
mainly due to the pivotal FIN-RACo and NEO-RACo studies [9,15]. 
2.3.2 Synthetic disease-modifying anti-rheumatic drugs 
Synthetic Disease Modifying Anti-Rheumatic Drugs (sDMARDs) are a heterogenous group 
of small molecule drugs, which have a positive impact on symptoms and radiological joint 
damage [6]. Biochemical and pharmacokinetic properties as well as cellular targets of 
sDMARDs vary from agent to another. Commonly used sDMARDs comprise methotrexate 
21 
(MTX), sulfasalazine (SSZ), hydroxychloroquine (HCQ), leflunomide and to a lesser extent 
intramuscular gold, cyclosporine and azathioprine [6,7]. Other sDMARD nowadays 
unavailable in Finland or considered obsolete and used to lesser extent include 
podophyllotoxine, auranofin and D-penicillamine. Cyclophosphamide is reserved for 
refractory cases not responding to other means of therapy. 
MTX is a mainstay and anchor drug in the treatment of RA due to its favorable 
efficacy/toxicity ratio [6].  Resembling folic acid, MTX is a competitive antagonist of 
folate-dependent enzymes. The mechanism of action for MTX is complex however, and 
while folate antagonism appears to play some role, bulk of the anti-inflammatory effect is 
mediated by an increase in endogenous adenosine release and the consequent down 
regulation of neutrophils, macrophages and T-cells [6,63,64].  MTX is administered either 
orally or parenterally (subcutaneously or intramuscularly) once a week. Folic acid should 
be used concomitantly with MTX to reduce gastrointestinal, mucosal and hematological 
side-effects.  
SSZ is a combination of sulfapyridine and 5-aminosalicylic acid, which breaks down to its 
components in the bowel [65]. Much like MTX, the anti-inflammatory effects of SSZ are 
mediated by increase in extracellular adenosine concentration [66]. An antimalarial drug 
nowadays used for autoimmune disorders, HCQ acts as a weak base, which allows it to 
enter cells and cause dysfunction in protein processing [67]. Subsequent downstream 
effects include reduced lymphocyte and natural killer cell activity and reduced 
autoantibody production. HCQ is associated with ocular toxicity in continuous use and has 
more modest efficacy in comparison to other sDMARDs, but is nevertheless frequently 
used is RA in particular in combinations with other sDMARDs. [65]. Leflunomide 
undergoes a rapid transformation into its active metabolite, which inhibits the synthesis 
of pyrimidine ribonucleotides and by doing so, the clonal expansion of activated 
lymphocytes [68]. Injectable gold has been used in treatment of RA for decades, but has 
largely been replaced by other sDMARDs with comparable efficacy, yet lesser side-effects 
[65]. Its mechanism of action is partially undisclosed, but known effects comprise reduced 
production prostaglandins, leukotrienes, IL-1 and oxygen radicals as well as down 
regulated proliferation of lymphocytes [65,69]. Isolated from fungus Hypocladium 
inflatum gams, Cyclosporine is used for prevention of allograft rejection in addition to 
being a potent anti-rheumatic agent [70]. As a calcineurin inhibitor, Cyclosporine inhibits 
T-cell activation and profileration by preventing transcription factors known as nuclear 
factor of activated T-cells (NFAT) from translocating to nucleus [71]. Like cyclosporine, 
azathioprine has been been used in solid organ transplantation preventing rejection. Its 
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mechanisms of action are diverse and comprise halting DNA replication, blocking de novo 
pathway of purine synthesis and interference with CD28 co-stimulation of T-cells.  
Glucocorticoids are a unique class of drugs invaluable in the treatment of chronic 
inflammatory conditions, including RA [6]. The anti-inflammatory and immunosuppressive 
effects of glucocorticoids have a rapid onset and are well characterized. Prednisolone, 
including its prodrug prednisone is the most frequently used. Although low-dose 
glucocorticoids are usually well-tolerated, high dosing may lead to severe side-effects 
such as osteoporosis, skin fragility and infections [72].  Glucocorticoids may also be 
administered as intra-articular injections.  
2.3.3 Biological drugs 
A sentinel cytokine or “the body’s fire alarm”, Tumor Necrosis Factor (TNF) is thought to 
have beneficial effects at low concentrations such as augmentation of host defense while 
at high concentration it can lead to excess inflammation and organ injury [73]. The 
efficacy of TNF-blockade in treatment of RA was demonstrated in the 1990s using two 
different approaches. Infliximab, a chimeric human-murine antibody binding both soluble 
and membrane bound TNF was approved by United States Food and Drug Administration 
(FDA) in 1999, accompanied by etanercept, a genetically engineered TNF receptor 2 fused 
to the Fc portion of human IgG1. The effects of TNF-inhibitors fall into two categories: 
blockade of TNF-receptor-mediated mechanisms and induction of transmembrane-TNF-
mediated mechanisms [73]. By preventing the activation of TNF-receptor by neutralizing 
TNF, TNF-inhibitors affect cell activation and proliferation, cytokine and chemokine 
production as well as ensuing cell recruitment, inflammation, immune regulation, 
angiogenesis and extracellular matrix degradation. Reverse signaling through 
transmembrane-TNF has been shown in vitro to induce cytokine suppression and 
endotoxin resistance, but it is unclear if such binding has functional consequences in 
patients. Administration of TNF-inhibitors may induce the formation of anti-drug-
antibodies, which reduce the clinical effectiveness of the treatments [74]. Etanercept is 
an exception however, as no neutralizing anti-etanercept antibodies have been detected. 
To date, five TNF-inhibitors have been approved in Finland, namely infliximab 
(Remicade®), etanercept (Enbrel®), adalimumab (Humira®), certolizumab pegol (Cimzia®) 
and golimumab (Simponi®). In 2013 European Medicines Agency (EMA) approved the first 
biosimilars infliximab (Remsima and Inflectra®) [75].  
TNF-inhibitors aside, four other biologic drugs based on equal number of different 
mechanisms of action have been approved for treatment of RA. Anakinra was the third 
biologic drug for the treatment of RA to enter the market after infliximab and etanercept.  
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It is a competitive IL-1 receptor antagonist and thus down regulates IL-1 signaling. IL-1 is 
known to exist both locally in the RA joint and as a systemic proinflammatory cytokine 
[76]. Although nowadays rarely used in the treatment of RA, anakinra has found a niche 
in the treatment of adult-onset Still’s disease and certain autoinflammatory syndromes 
such as cryopyrin associated periodic syndrome (CAPS) [6,77–79]. IL-6 in a pro-
inflammatory cytokine contributing to host defense, and like TNF, its continuous 
production plays a significant role in the pathogenesis of RA [80]. Tocilizumab is a 
humanized monoclonal anti-body inhibiting both soluble and membrane bound forms of 
IL-6, which leads to effects on B-cells, T-cells, hepatocytes and various other cells.  A CD20 
antigen anti-body originally developed for the treatment of B cell lymphoma, rituximab 
induces apoptosis on CD20 positive B cells, which in turn impairs antigen presentation to 
T cells as well as cytokine production [81]. Rituximab is usually administered as fixed 
1000mg infusions at intervals from 6 to 8 months. In addition to antigen presentation, the 
activation of T cells requires a second signal mediated by co-stimulatory molecules, of 
which CD28 may be the most important [82]. Abatacept is a fusion protein directly 
targeting T cells by a mechanism called ‘costimulatory blockade’ by binding to and 
blocking the CD80/86 present on the antigen-presenting cells and thus, inhibiting 
CD80/86 mediated stimulation of T cells via CD28 located on the surface of T cell. 
Consequently, cytokine production and B-cell activation are down regulated. 
2.3.4 Efficacy and safety of biological drugs in randomized clinical trials 
2.3.4.1 Infliximab 
Studies have demonstrated that the combination of infliximab and MTX is superior in 
efficacy compared to MTX alone [83–85]. Maini et al. showed that 27% of the infliximab-
treated (3mg/week every 8 weeks) patients reached ACR50 response at 30 weeks while 
the same outcome was reached by only 4% of the patients on MTX monotherapy [85]. 
Lipsky et al. 2000 confirmed the results by showing that while only 8 per cent of 
methotrexate treated patients reached ACR50 response at 54 weeks, the infliximab 
patients fared much better (21% to 39%) in a dose-responsive manner [84]. In a study by 
St Clair et al. 32.1, 45.6 and 50.4 per cent of patients reached ACR50 response at 54 
weeks in MTX alone, infliximab 3mg/kg + MTX and infliximab 6mg/kg + MTX groups, 
respectively [83]. St Clair et al. observed a higher incidence of serious adverse events 
among infliximab users (11% vs. 14%) as compared to patiens on MTX only, which was 
not seen in the other two studies. However, the other studies detected an elevated 
incidence of mild infections as well [83–85].  
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2.3.4.2 Etanercept 
Moreland et al. compared etanercept at doses of 10mg and 25mg per week to placebo 
and found that either dosage of etanercept was associated with statistically significantly 
higher proportion of patients reaching ACR50 response at six weeks [86]. In a study by 
Klareskog et al. ACR50 was reached by 69%, 48% and 43% of etanercept + MTX, 
etanercept alone and MTX alone treated patients [87,88]. Keystone et al. confirmed 
previous findings on efficacy and showed that etanercept can be administered once a 
week at dose of 50mg in addition to standard dose of 25mg twice a week. No statistically 
significant differences in the incidence of adverse event between etanercept and the 
comparator treatment, with the exception of injection site reactions were found [86–88]. 
2.3.4.3 Adalimumab 
The ARMADA trial was set to study the efficacy and safety of adalimumab with three 
different dosages among patients with active RA despite the ongoing MTX treatment. 
ACR50 was reached by 8.1, 31.9, 55.2 and 42.5% of the patients on placebo or 20, 40 or 
80mg of adalimumab every other week [89]. Similar results were obtained in a study by 
Keystone et al. where 9.5, 37.7 and 41.5% of patients qualified for ACR50 response at 
week 52 among placebo + MTX, adalimumab 20mg weekly + MTX and adalimumab 40mg 
weekly treated patients, respectively [90]. In patients with severe RA, adalimumab 
monotherapy was more efficacious as any of the four tested dosage regimens than 
placebo [91]. Exposure to adalimumab was not associated with greater risk for adverse 
events compared to placebo although mild adverse events such as headache, rash and 
injection site reactions occurred more frequently in the adalimumab group [89–91]. 
2.3.4.4 Golimumab 
The results obtained by Kay et al proved the combination of golimumab and MTX to be 
more efficacious than MTX alone, measured by the proportion of patients reaching ACR50 
response at week 16 [92]. In another study Keystone et al. confirmed these findings 
although by week 24 the differences between MTX and golimumab monotherapies were 
no longer statistically significant [93]. Emery et al. also compared golimumab 
monotherapy and the combination of golimumab and MTX to MTX alone and found that 
at week 24 there was no statistically significant difference in efficacy [94]. The safety 
profile of golimumab in clinical trials was comparable to MTX although nausea, injection 
site erythema and headache were more common among golimumab treated patients 
[92–94]. 
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2.3.4.5 Certolizumab pegol 
The efficacy and safety of certolizumab pegol was compared to MTX by Fleischmann et al. 
and the results showed that a statistically significantly greater percentage of certolizumab 
pegol treated patients reached ACR50 response at week 24 (22.7% vs. 3.7%) compared to 
ones receiving placebo [95]. Another trial comparing the combination of certolizumab 
pegol and MTX to MTX alone showed that certolizumab pegol is also efficacious as a 
combination treatment [96]. Serious adverse events including serious infections and 
malignancies were observed more frequently among the certolizumab pegol treated 
patients. 
2.3.4.6 Anakinra 
Early studies established Anakinra to be better than placebo both in achieving clinical 
response and delaying radiographic progression [97,98]. Cohen et al. compared MTX 
monotherapy to combination of anakinra and MTX and found that the combination 
therapy was associated with statistically significantly better efficacy, measured as the 
proportion of patients reaching ACR50 response (17%vs. 8%) [99].  Adverse events 
occurred more frequently in the anakinra group (90%) compared to MTX group (81%).  
2.3.4.7 Rituximab 
In a trial, which aimed to explore the efficacy and safety of rituximab among patients with 
previous unsuccessful TNF-inhibitor treatments, patients on rituximab + MTX reached 
ACR50 response at week 24 significantly more often (27% vs 5%) than the control group 
[100]. Overall, 88% of placebo treated patients reported an adverse event in comparison 
to 85% of the rituximab-treated patients. Similar results were obtained by Emery et al. 
who also found that while higher dose of rituximab (2x1000mg) was associated with 
similar efficacy as lower dose (2x500mg) measured as proportion of patients reaching 
ACR50, greater percentage of patients among high-dose group reached ACR70 response. 
Subsequent infusions of rituximab have been shown to maintain the clinical response 
[101].  
2.3.4.8 Abatacept 
Abatacept was proven an efficacious and safe co-therapy to MTX in a trial by 
Westohovens et al. [102]. The proportion of patients reaching ACR50 response at 1 year 
was 57.4% in abatacept + MTX group, as compared to 42.3% among patients treated with 
MTX alone. Safety of abatacept was favorable when admistered as a co-therapy with non-
biologic DMARDs although patients with Chronic Obstructive Pulmonary Disease might be 
predisposed to increased rate of adverse events during abatacept treatment [103].   
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2.3.4.9 Tocilizumab 
Tocilizumab was tested against placebo in a trial that allowed co-medication with 
sDMARDs, revealing that the tocilizumab-treated patients reached ACR50 response 
significantly more often (37.6% vs. 9.0%) than patients receiving placebo [104]. The 
results were similar among patients with previous unsuccessful treatments with TNF-
inhibitors [105]. In a comparison between tocilizumab and MTX monotherapies, 
tozilizumab was associated with better outcomes although the difference was 
considerably more subtle than in previous comparisons [106]. Safety of tocilizumab was 
deemed comparable to MTX in all three trials [104–106].  
2.3.4.10 General features of RCTs studying the efficacy and safety of biological drugs in RA 
Numerous RCTs have addressed the efficacy and safety of biologic drugs in treatment of 
RA; the first publications dating back do early 1990s [107]. Vast majority of the RCTs 
compare the biologic drug to placebo or MTX, which do not represent the current 
treatment recommendations on the best synthetic treatment [8,108]. In particular from 
the point of view of Finnish treatment strategy, effective combinations of DMARDs should 
be used at appropriate doses, preferably comprising MTX, SSZ, HCQ and low-dose 
prednisolone. Few such studies have emerged lately, providing better generalizability to 
clinical practice. A Swedish non-blinded interventional trial randomized patients with 
unsatisfactory response to MTX alone to additionally receive either HCQ and SSZ or 
alternatively, infliximab. The patients receiving infliximab had a slightly better ACR50 
response at 12 (25% vs. 15%) and 18 (30% vs. 19%), but at 24 months the difference was 
no longer statistically significant (30% vs. 22%) [109]. Meanwhile in a Finnish trial, 
Leirisalo-Repo et al. investigated whether the addition of infliximab to RACo combination 
therapy in the so called NEO-RACo study would yield improved outcomes [15]. According 
to the results, infliximab-treated patients were statistically non-significantly more often in 
remission at two years after the therapy onset (66% vs. 53%) and also non-significantly 
more often achieved ACR50 response.   
Despite the wealth of information on biologic drugs being compared to placebo or MTX, 
few trials to date have compared individual biologic agents to  one another [19,110]. One 
such study was the AMPLE trial, which compared abatacept to adalimumab among 
biological-naïve patients with concomitant MTX treatment and revealed that the two 
biologic drugs, although based on different mechanism of action, are comparable in 
efficacy and safety.  
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2.3.5 Effectiveness and adverse effects of biologic drugs in observational studies 
2.3.5.1 Treatment response and drug survival 
The effectiveness of biologic drugs in treatment of RA has been studied in several 
European countries using data from prospective cohort studies although most literature 
concerns only TNF-inhibitors [111–114]. Moderate and good EULAR treatment responses 
at six months were achieved by 67 – 85% and 17 – 52%, respectively (Table 2). In 
multivariate regression analyses, etanercept and adalimumab were generally associated 
with better treatment response compared to infliximab [111–114]. Most commonly 
identified predictors of treatment response were concomitant sDMARDs, especially MTX 
and baseline disease activity as well as smoking [111–113,115]. No difference has been 
observed in effectiveness of TNF-inhibitors between men and women [116]. In case of 
treatment failure, it has been shown that treatment with another TNF-inhibitor may be 
beneficial [117].  
Table 2. Percentage of RA patients achieving at least moderate and good (latter in parentheses) 
EULAR response after 6 months of treatment onset. 
Study Infliximab Etanercept Adalimumab Pooled TNF-
inhibitors 
Hyrich et al. 
2006 [111] 
69% (19%) 67% (17%) - 68% (18%) 
Hetland et al. 
2010 [112] 
71% (34%) 81% (42%) 85% (52%) 77% (41%)
1
 
Canhao et al. 
2012 [114] 
(33%) (39%) (40%) (38%)
1
 
Flouri et al. 2014 
[113] 
69% (20%) 78% (19%) 72% (24%) 72% (21%)
1
 
1
Pooled results not reported, but calculated based on available data 
In Denmark, 19% and 34% of RA patients discontinued their first TNF-inhibitor treatment 
within six and twelve months of treatment onset, respectively [112]. The most common 
reasons for discontinuation were lack of effectiveness and adverse events. In a Northern-
Italy based cohort, 79%, 65% and 53% of patients remained on the treatment after 12, 24 
and 36 months of treatment onset, respectively [118]. Results by Hyrich et al. show that 
81% of TNF-inhibitor users remain on treatment after 6 months [111]. Adalimumab and 
etanercept have been associated with better drug survival as compared to infliximab 
[112,113]. 
2.3.5.2 Serious infections  
Patients with RA have an increased risk for infections, possibly due to both 
immunosuppressive medication and the disease process itself [119]. The crude incidence 
rate of serious infections during exposure to TNF-inhibitors has been observed to range 
28 
from 2.6 to 5.5 events per 100 patient years (Table 3). Even though the information from 
RCTs has not consistently shown an increased risk for infections among patients treated 
with biologic drugs compared to sDMARD-treated patients, observational research has 
been performed to confirm the findings [120]. After adjusting for possible confounding, 
most observational studies have found a small and often statistically insignificant increase 
in the incidence of serious infections compared to sDMARDs [120–122]. A recent 
systematic review concluded that in the light of current evidence, biologic drugs are 
associated with increased risk for infections (Table 4) [24]. The risk for infections may be 
especially high during the first six months of treatment, possibly because the subset of 
patients susceptible to infections are less likely to stay on the treatment [123]. 
Furthermore, the incidence of certain types of serious infections has been detected to be 
higher among TNF-inhibitor-treated patients. TNF plays a role in defence against 
Mycobacterium Tuberculosis and the reactivation of tuberculosis is a recognized safety 
issue with TNF-inhibitors and is now being screened routinely before biologic therapy [7]. 
Dixon et al. compared the incidence of tuberculosis among TNF-inhibitor treated patients 
and found that etanercept was safer in that respect compared to infliximab and 
adalimumab [124]. Also, the risk for serious skin infections and shingles has been found to 
be elevated during exposure to TNF-inhibitors [125]. Cases of serious infections among 
Finnish RA patients using TNF-inhibitors have also been described in the literature [126]. 
Although less data is available for rituximab, compared to sDMARDs it does not seem to 
predispose patients to either infections [127]. MTX and glucocorticoids have been shown 
to increase the risk for serious infections when used concomitantly with TNF-inhibitors 
[123,128,129]. 
Table 3. Crude incidence rates per 100 patient years and corresponding 95% confidence intervals 
of serious infections during exposure to TNF-inhibitors. 
Study Infliximab Etanercept Adalimumab Pooled TNF-
inhibitors 
Lane et al. 2011 [129] - - - 3.6 (3.2-4.0)
1
 
Komano et al. 2011 [128] - - - 2.6 (1.2-4.1) 
Strangfeld et al. 2011 
[130] 
- - - 4.8 (4.1-5.7)
2
 
Galloway et al. 2011 [123] 4.6 (4.2-5.0) 3.8 (3.5-4.2) 4.3 (3.9-4.7) 4.2 (4.0-4.4) 
Sakai et al. 2012 [131] 4.8 (3.3-6.7) 5.6 (4.1-7.4) - 5.5 (4.4-6.8) 
Van Dartel et al. 2013 
[121] 
3.9 (3.3-4.4) 1.7 (1.1-2.2) 2.6 (2.2-3.0) 2.6 (2.2-3.1)
1
 
1
Confidence intervals not reported, but calculated based on available data; 
2
Data on the first year 
of treatment; TNF=tumor necrosis factor 
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Table 4. The adjusted hazard/risk ratios for infections among patients exposed to TNF-inhibitors in 
comparison to sDMARD users (modified from Ramiro et al. 2014 [24]) 
Study Exposure Control Adjusted effect size 
(95% CI) 
Grijalva et al. 2010 [132] TNF-inhibitors MTX HR 1.3 (0.8-2.2) 
Greenberg et al. 2010 
[133] 
TNF-inhibitors+MTX MTX HR 1.1 (1.0-1.3) 
Grijalva et al. 2011 [122] TNF-inhibitors sDMARDs HR 1.1 (0.9-1.2) 
Lane et al. 2011 [129] TNF-inhibitors sDMARDs HR 1.2 (1.0-1.5) 
Komano et al. 2011 [128] ETA/IFX sDMARDs RR 2.4 (1.1-5.1) 
Galloway et al. 2011 [123] TNF-inhibitors sDMARDs HR 1.2 (1.1-1.5) 
Strangfeld et al. 2011 
[130] 
TNF-inhibitors sDMARDs HR 1.8 (1.2-2.7) 
Sakai et al. 2012 [131] ETA/IFX sDMARDs RR 2.0 (1.3-3.2) 
TNF=tumor necrosis factor; MTX=methotrexate; ETA=etanercept; IFX=infliximab; 
sDMARD=synthetic disease-modifying anti-rheumatic drug; HR=hazard ratio; RR=risk ratio; 
CI=confidence interval 
 
2.3.5.3 Malignancies 
Due to the role of TNF in host defence, it was hypothesized that its blockade might lead 
to increased risk of malignancies, including lymphomas [134]. Controversially, increased 
TNF-levels have also been associated with increased risk for certain types of malignancies.  
Between the introduction of biologic drugs to US market in 1998 and 2000, 26 cases of 
lymphomas were reported to the FDA, rising concerns of the serious adverse effects 
[135]. The association between elevated disease activity and excessive inflammation and 
increased risk  of lymphomas, leukaemia and myelomas has made definite causal 
conclusions difficult [136–138]. The incidence rates per 100 patient years of solid cancers, 
lymphomas or leukemias and nonmelanoma skin cancers among RA patients using TNF-
inhibitors has been observed to be 0.91, 0.13 and 0.31, respectively [139]. Current 
evidence does identify discrete types haematological malignancies and skin tumours that 
may be affected by the exposure to TNF-inhibitors, but the overall risk is not increased 
(Table 5) [24,126,136,140–142]. It is unclear if patients with history of previous 
malignancy should be treated differently [24]. In Finland, TNF-inhibitors are avoided in 
patients with previous malignancy, nevertheless [7].  
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Table 5. The adjusted hazard/risk ratios for all types of malignancies among patients exposed to 
TNF-inhibitors in comparison to sDMARD users (modified from Ramiro et al. 2014 [24]) 
Study Exposure Control Effect size (adjusted) 
Askling et al. 2009 [142] TNF-inhibitors sDMARDs HR 1.0 (95% CI 0.7-1.4) 
Strangfeld et al. 2010 [143] TNF-inhibitors sDMARDs HR 0.7 (95% CI 0.4-1.1) 
Carmona et al. 2011 [144] TNF-inhibitors sDMARDs HR 0.5 (95% CI 0.1-2.5) 
Haynes et al. 2013 [139] TNF-inhibitors sDMARDs HR 0.8 (95% CI 0.6-1.1) 
TNF=tumor necrosis factor; sDMARD=synthetic disease-modifying anti-rheumatic drug; HR=hazard 
ratio; RR=risk ratio; CI=confidence interval 
 
2.3.5.4 Joint replacement surgery  
Recent Finnish study by Jämsen et al. found a trend between the increased use of 
sDMARDs and biologics and reduced need for joint replacement surgery in RA during the 
years 1995-2010 [35]. Similar trends have been observed elsewhere as well [17,34]. 
Regardless, another Finnish study was not able to show causality between the intensified 
therapy and then need for large joint replacement surgery [145]. Presently, there is 
insufficient information to conclude to what extent the introduction of biologic 
treatments has affected the need for joint replacement surgery and what can be 
explained with other factors. 
DMARDs as well as biologic drugs aim to control the inflammation thus preventing the 
joint damage and premature need for joint replacement, however, especially biologic 
drugs have been suspected to predispose to periprosthetic infections [146–148]. Patients 
with RA exhibit a distinct cellular response to wear particles from artificial joints, which 
can lead to aseptic loosening of the prosthesis [149]. This process may be however, be 
mitigated by TNF-inhibitor treatment. A review article published in 2007 recommended 
performing elective surgery before initiating biologic treatment while more recent 
guidelines advice withholding biologic treatment one week before and after the 
operation [150,151]. It remained uncertain whether sulfasalazine and leflunomide should 
be discontinued before surgery, whereas methotrexate and hydroxychloroquine were 
considered safer. In the study by Bongartz et al. perioperative discontinuation of DMARDs 
and biologics did not statistically significantly reduce the risk of infection [146]. 
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2.3.5 Usage and costs of biological drugs in Finland 
The first biologic drugs available for treatment of RA in Finland were infliximab and 
etanercept, which were authorized throughout European Union in 1999 and 2000, 
respectively [152,153]. During the years 1999-2002 infliximab was the drug of choice 
([154], personal communication Voipio Tiina/FIMEA October 2012) (Figure 1).  Starting 
from 2003, etanercept and adalimumab were reimbursed by the Social Insurance 
Institution of Finland (KELA), which made them affordable to the patients and therefore, 
not influencing the hospital budgets. Consequently, majority of new biologic treatments 
were started using either one of the self-administered drugs instead of the intravenously 
administered infliximab. The use of biologic drugs other than infliximab, etanercept and 
adalimumab has been growing since, but was nevertheless marginal compared to the 
three aforementioned in 2012.  In 2012, the total usage of biologic drugs was 1.85 Daily 
Defined Doses (DDD) per 1000 persons per day. Based on these numbers, estimated 
0.19% of Finnish people or 10 300 persons were continuously using biologic drugs in 
2012. On the other hand, the KELA records reveal that 7 823 people received co-
payments from self-administered biologic drugs in 2012 ([11], personal communication 
Saastamoinen Leena/KELA September 2009) (Figure 2).  The total medical costs of self-
administered biologic drugs in 2012 were 97 M€, or 5.4% of all outpatient medical costs 
combined. Both the annual number of patients treated with self-administered TNF-
inhibitors and the corresponding costs have grown more than ten-fold during a period of 
ten years. Altogether, 3.8 million people received co-payments from KELA in 2012 
meaning that the medical costs of an average biologic drug user exceeds the population 
average by 27-times, not including other medications the biologic drugs user might have.  
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Figure 1. Use of biological therapies in Finland in 1999-2012 ([154], personal 
communication Voipio Tiina/FIMEA October 2012) 
 
Figure 2. Social Insurance Institution of Finland (KELA) records on the number of users 
and total costs of biologic drug users in Finland 2003-2012 ([11], personal communication 
Saastamoinen Leena/KELA September 2009). 
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3 AIMS OF THE STUDY 
 
1. To identify, evaluate and summarize relevant published data on TNF-blockers in the 
treatment of RA and to perform an indirect comparison between the drugs (Study I).  
2. To perform a cross-sectional overview on demographics, disease activity and 
medication of RA patients in Finland (Study II). 
3. To investigate the incidence of serious infections and malignancies among RA patients 
treated with sDMARDs, TNF-inhibitors or rituximab (Study III).  
4. To assess the effectiveness of biologic drugs on the incidence of joint replacement 
surgery and its outcomes in comparison DMARDs (Study IV). 
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4 MATERIALS AND METHODS 
4.1 Systematic review (I) 
According to inclusion criteria patients had to be at least 16 years of age; be diagnosed 
with RA using ACR 1987 criteria; and be randomized either to intervention or control 
group. Studies were to have one (or more) of the TNF-inhibitors (infliximab, etanercept, 
adalimumab, certolizumab pegol or golimumab) as intervention and either placebo or 
combination of placebo and methotrexate as control. The included studies were to report 
on efficacy in terms of ACR response and safety. 
Search designed by a librarian comprised the terms rheumatoid arthritis, anti-TNF, 
infliximab, etanercept, adalimumab, golimumab, certolizumab pegol, randomized clinical 
trials and systematic review. Detailed search strategy for (Ovid) Medline is available as 
Appendix 1. References identified from (Ovid) Medline, Cochrane library (Cochrane 
Central register of Controlled Trials, Cochrane Database for Systematic Reviews, Health 
Technology Assessment, Database of Abstracts of Reviews of Effects, NHS Economic 
Evaluation, Cochrane Methodology Register), SCOPUS (including Embase), ISI web of 
knowledge imported to reference management software (RefWorks) and duplicate 
entries were removed using an automated feature. There were no restrictions on study 
language.  
References were evaluated by two individual investigators using pre-defined inclusion 
criteria. Decision for inclusion was made on consensus or by a third investigator (YTK) in 
case of disagreement. Evaluation was based on title and abstract of the reference 
whenever available. Full text articles from potentially relevant references were obtained 
in electronic or printed format and re-evaluated for inclusion by the same investigators as 
before. The acronym PICOS (patients, interventions, comparators, outcomes and settings) 
was used to assess if the references fully complied with the inclusion criteria. Multiple 
reports from a single study were considered as one study. 
Studies included were evaluated for an eventual bias using methods described in the 
Cochrane handbook by two independent assessors [155]. The effect of possible bias on 
results was studied by performing all meta-analyses twice with possibly biased RCTs 
included and excluded. 
Data on study design, patient status and background, efficacy and safety were extracted 
from the publications using an Excel data extraction form by two independent 
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researchers. Whenever results of a single study were reported in multiple publications, all 
available data was acquired and merged. 
Data were analyzed using the intention to treat results from the included studies and 
pooled with Cochrane Collaboration Review Manager 5.0 software. Sensitivity analyses 
were employed to account for the possible bias. Efficacy and safety were analyzed using 
dichotomous data to obtain risk ratios. Dichotomous efficacy data included ACR 20%, 50% 
and 70% improvements whereas dichotomous safety data was composed of the 
proportion of patients who experienced an adverse outcome or discontinued the 
treatment due to adverse events. Heterogeneity was evaluated via subgroup analysis 
using Chi square and I2-statistics and random effects model was used to account for the 
diversity of the studies [155]. 
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4.2 Cross-sectional study (II) 
Inclusion to the (Reuman Aktiivisuuden MIttaaminen) RAMI cross-sectional study was 
limited to RA patients diagnosed either according to the ACR 1987 inclusion criteria or 
alternatively, as a clinical diagnosis [27]. Additionally, patients had to be at least 16 years 
of age and be treated within the specialized outpatient healthcare. The study was a cross-
sectional in nature and thus data was collected from a single time point. The participating 
rheumatology clinics were to enroll consecutive patients until the planned study size of 
1000 patients was reached. The data to be collected comprised information on 
demographic, disease activity and medication –related variables and was collected using 
a pre-designed data collection form, which was divided to two sections to be filled by 
rheumatologist and patient. Alternatively, the data could be collected using an electronic 
patient monitoring software (GoTreatIt; DiaGraph, Kristiansand Norway). Afterwards, 
data from forms were imported into an electronic database (Access 2010, Microsoft 
Redmond) and merged with the electronically collected data. 
Patient self-report comprised information on educational background and current 
employment status along with data on sick leaves, pension and work disability as well as 
current smoking status. The number of joint replacement surgeries was also inquired as 
they are not reliably recorded in the hospital records. Furthermore, the patient self-
report comprised visual analogue scales for pain and global assessment along with Health 
assessment questionnaire disability index (HAQ-DI). Basic education was defined as either 
having only completed high school, vocational school or less; equaling as up to twelve 
years of education.  
Disease activity score based on 28-joint count (DAS28), simplified disease activity index 
(SDAI), clinical disease activity index (CDAI) and fulfillment of ACR/EULAR 2011 remission 
criteria were calculated in data analysis based on their respective formulas. Descriptive 
data are presented either as means and medians with interquartile range (IQR) or 
percentages. The data were analyzed in SPSS 20 (IBM, Armonk New York) using either 
parametric or non-parametric tests, depending on the distribution. Percentages were 
calculated with and without missing cases to estimate the effect of missing data on the 
results; however missing data was not imputed. 
Ethical statement was applied from the ethical board of each participating hospital 
district. Written consent was obtained from each enrolled patient. 
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4.3 Cohort studies (III and IV) 
The study population was identified from the national register for biologic treatment in 
rheumatic diseases (ROB-FIN) and the hospital records of Central Finland Central Hospital 
with the latter providing all sDMARD users. A prospective cohort study designed to 
monitor the effectiveness and safety of biologic drugs in treatment of rheumatic diseases 
and based on structured data collection forms submitted by rheumatologists on patients’ 
routine care visits to outpatient specialized healthcare; ROB-FIN has follow-up data dating 
back to year 1999. Reporting is instructed to occur at the baseline of the biologic 
treatment, 3 and 6 months after the treatment onset and semiannually thereafter. The 
electronic hospital records collected using GoTreatIT patient monitoring software were 
retrieved from 2007 onwards. Additionally, survey-based data forming a time-series on 
RA patients treated in Central Finland Hospital district 1998-2006 was used to extend the 
sDMARD follow-up for the analysis of joint replacement operations (IV) [156].  
To be included in the cohort studies, patients had to have a confirmed diagnosis of RA 
(either meeting the ACR 1987 criteria or a clinical diagnosis) and had at least one 
recorded visit during the exposure to either biologic or synthetic DMARDs [27]. Additional 
inclusion criteria for the analysis of serious infections and malignancies (III) were 
treatment onset prior to December 31 2011 and treatment with either infliximab, 
etanercept, adalimumab or rituximab. Additionally, only biologic-naïve sDMARD users 
were included. The patient could contribute to several medication groups as long as it did 
not violate the inclusion criteria. The inclusion criteria for the analysis of joint 
replacement surgery (IV) considered all biologic and synthetic DMARD users having 
commenced their treatment prior to November 9th 2010 were included and accumulated 
at least two recorded visits eligible for the study.  
Follow-up time for the study on serious infections (III) was defined either as the reported 
medication start and stop date, or alternatively in the absence of this information, as the 
time between the first and the last visit while on drug. Additionally, a six month lag-time 
was introduced to capture the adverse events taking place soon after the discontinuation 
of the exposure. However, the follow-up was truncated at the initiation of another 
biologic treatment or at December 31 2011. Baseline visit was defined as the first visit 
during the exposure or at most three months before the treatment onset unless the 
patient was on another biologic treatment.  For the analysis of joint replacements (IV), 
follow-up period was defined as the time between the first and the last recorded visit 
while on biologic treatment. No lag-time was employed and the follow-up was truncated 
at November 9th 2010. 
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Data on study endpoints, serious infections, malignancies and joint replacement 
operations were acquired from National Hospital Discharge Register (HILMO), National 
Cancer Registry and the Implant registry, respectively [157–159]. Data on infections, 
malignancies and joint replacement operations were available to us from 1998 to 2011, 
1953 to 2011 and 1980 to 2010, respectively. No evaluations of causality between the 
exposure and outcome were made; instead all outcomes occurring during the follow-up 
period were included. Post-operative infections were excluded from the analysis of 
serious infections in study (III), but included in study (IV).  
The results are reported as medians with interquartile ranges (IQR), counts, incidence 
rates and incidence rate ratios (IRR). The 95% confidence intervals (95% CI) for IRs were 
retrieved from Poisson distribution based on the crude rates. Baseline differences 
between the groups were analyzed using analysis of variance, chi-squared test, Kruskal-
Wallis or Mann-Whitney’s U-test test, as appropriate. In the analysis of serious infections 
and malignancies (III), the IRRs were modelled using Poisson regression with adjustement 
for overdispersion accompanied by robust standard errors where appropriate. A full 
model where all observed and potentially relevant confounders were included was used.  
Multiple imputation (MI) with predictive mean matching and 20 imputed datasets was 
used to create the imputed data, which involved three steps [160]. First, several slightly 
different dataset were created. Second, the regression analyses were performed 
separately in each. And third, the correlation coefficients and standard errors were 
pooled together. In the analysis of joint replacements (IV) patients were matched using 
propensity score estimated via logistic regression, facilitating the comparison of the 
results of the matched patients without further use of regression analyses [161]. Kapplan-
Meier survival analyses were used for the life-time analysis of joint replacement 
operations with log-rank tests for subgroup differences. Data were analyzed using PASW 
18.02 statistical data package (IBM, Armonk, NY), SPSS 22.0 statistical data package (IBM, 
Armonk, NY) and R statistical programming language version 3.1.0 (R Foundation for 
Statistical Computing, Vienna, Austria). 
An ethical consent for the study was granted by the ethical board of the Division of 
Internal Medicine at Helsinki University Central Hospital (HUCH), while the study approval 
was acquired from the National Institute for Health and Welfare (THL). Additionally, all 
patients enrolled to ROB-FIN had given their informed consent. Data from different 
sources were merged on a patient level using unique social security numbers and 
anonymized to conceal the patient identity. 
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5 RESULTS 
5.1 Systematic review (I)  
5.1.1 Literature search and study selection 
Altogether, 5308 references of which 1623 were excluded as duplicates, were identified 
from electronic databases by a systematic literature search performed in February 2010. 
Additionally, 146 references were added via “search alerts”, which extended time 
coverage of the search to 30.6.2010. No additional references were identified from 
alternative sources including clinical trial registers. Seventy six potentially relevant 
references were re-evaluated based on full text. Full text was unavailable for 12 studies 
most of which were conference abstracts identified from ISI Web of Knowledge [107,162–
172]. Patients, interventions, controls, outcomes or design of the studies did not meet the 
inclusion criteria of the systematic review in 17 publications [173–189]. Five review 
articles, one letter to the editor [190] and one erratum [191] were excluded. Several of 
the remaining 41 publications were reporting on a single study and were thus merged 
into one [19,83–92,94–96,192–217]. From the 26 clinical trials included in the systematic 
review, adalimumab was used in 8,  etanercept in 7 , infliximab in 5, golimumab in 3 and 3 
certolizumab pegol in 3 for intervention. A flowchart of the study selection process is 
presented in Figure 3.  The included trials have 9862 patients of which 6780 and 3082 
were in intervention and control groups, respectively (Appendix 2).  
5.1.2 Evaluation for bias 
A potential source of bias was discovered in five trials included in the systematic review. 
In many clinical trials there was an early escape route for patients with insufficient 
treatment response to avoid rapid disease progression. In some studies this was 
implemented by considering all patients failing to meet a pre-defined treatment response 
criteria (e.g. ACR 20 % improvement) as “non-responders” before the actual efficacy 
assessment. While this may be for the best interest of the study subjects, it may 
introduce a bias to the evaluation of the efficacy results since some of these patients 
could have later reached treatment response.  
5.1.3 Efficacy 
The primary efficacy endpoint of our study was the risk ratio of 50 % improvements in the 
ACR-treatment response criteria at six months between intervention and control group. 
Fourteen trials were included and of them 2 used infliximab, 2 etanercept, 5 adalimumab, 
2 golimumab and 3 certolizumab pegol for intervention. As a group, TNF-inhibitors 
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reached a risk ratio of 4.07 (95 % CI 2.70-6.13) regarding the achievement of the efficacy 
endpoint compared to controls. For infliximab, etanercept, adalimumab, golimumab and 
certolizumab pegol the corresponding figures were 3.08 (0.91-10.43), 8.61 (3.55-20.86), 
4.34 (3.30-5.70), 1.56 (0.93-2.60) and 5.95 (3.97-8.92), respectively (Figure 4).  
 
Figure 3. Flowchart of the study selection process 
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Figure 4. Forest plot of the ACR 50 response at 6 months (Aaltonen et al. 2012 [218]) 
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Patients on combination therapy had significantly higher ACR outcomes than the ones 
treated with MTX alone at all time points. A statistically significant difference was 
revealed between ACR 20 risk ratios of certolizumab pegol (95% CI 5.08, 3.46-7.48) and 
golimumab (1.61, 0.94-2.76). In a sub analysis of trials in patients who had previously 
used MTX, the results were similar. In comparison to MTX, golimumab combination 
therapy was still inferior in ACR 20 efficacy at 6 months to certolizumab pegol 
combination therapy, with risk ratios of 2.14 (1.59-2.89) and 5.08 (3.46-7.48), 
respectively. At six months patients previously naïve to MTX are statistically significantly 
less likely to reach either ACR 20, 50 or 70 treatment responses compared to patients 
who had already been previously treated with MTX. The combination of TNF-inhibitor and 
MTX was superior in efficacy to monotherapy with a TNF-inhibitor at almost all time 
points. All four TNF-inhibitors were more efficacious than placebo with the estimates of 
risk ratios ranging from 2.74 (95% CI 1.76-4.26) – 12.31 (1.64-92.41). Increasing the dose 
of TNF-inhibitor provided no additional efficacy compared to regular doses except 12 
months with possibly biased results excluded. 
The sensitivity analyses based on the results of the bias assessments did not reveal any 
statistically significant bias on the efficacy results. Occasionally, however, the statistical 
significance between intervention and control groups disappeared due to reduced 
number of studies. In the sensitivity analyses, the estimate of the risk ratio decreased, 
increased or remained the same in 52%, 45% and 3% of cases, respectively. However, all 
certolizumab pegol studies were potentially biased and the effect of bias on the results 
could not be evaluated.  Significant heterogeneity was present in the first analysis 
comparing any intervention to any control, but diminished as the comparisons were 
stratified into smaller comparisons.  
5.1.4 Safety 
The primary safety endpoint of the systematic review was the discontinuation of study 
due to adverse events. There were 25 studies with 6292 patients in the intervention and 
2994 in the control group in this analysis.  As a group, the TNF-inhibitors did not 
statistically significantly differ from the control (RR 1.26, 95% CI 0.93-1.71). While the 
patients on infliximab (3.22, 1.76-5.91), adalimumab (1.59, 1.13-2.23), and certolizumab 
pegol (2.72, 1.23-6.01), had an increased risk to discontinue, the patients on etanercept 
(0.71, 0.54-0.92) had a decreased risk (Figure 5). Patients using certolizumab pegol had a 
higher risk to experience a serious adverse event than patients on etanercept with risk 
ratios of 2.24 (1.38-3.63) and 0.90 (0.68-1.20), respectively. Infliximab, etanercept and 
golimumab increased the likelihood of an injection or infusion reaction while adalimumab 
and certolizumab pegol did not statistically significantly differ from the controls in this 
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respect. In the comparison of combination of TNF-inhibitor and MTX to MTX alone, 
combined results from all TNF-inhibitors reached statistical significance (1.37, 1.01-1.87). 
The comparison of TNF-inhibitors and placebo showed a trend of increased risk of 
adverse events from TNF-inhibitors, but only the increase in the frequency of injection 
reactions was statistically significant (RR 3.69, 95% CI 1.03-13.23). Certolizumab pegol 
was the only TNF-inhibitor, which increased the risk to experience an adverse event 
compared to placebo (1.31, 1.08-1.26). Increased dose of the TNF-inhibitors did not 
increase the frequency of discontinuations due to adverse events (RR 0.98, 95% CI 0.72-
1.35), but the likelihood to experience an unspecified adverse event was reduced 
compared to normal doses (0.93, 0.89-0.97). Patients on high doses of infliximab were 
also less likely to suffer from infusion reactions compared to those on regular doses (0.73, 
0.56-0.94).   
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Figure 5. Forest plot of the number of discontinuations due to an adverse event.  
(Aaltonen et al. 2012 [218]) 
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5.2 Cross-sectional study (II)  
5.2.1 Patients and disease characteristics 
Overall, 890 patients were enrolled into the study. The data collection took place 
between November 2011 and May 2012 in 14 sites in 6 hospital districts. Data collection 
paper forms were used to collect data on 76% of patients while remaining 24% were 
retrieved from hospital records using GoTreatIT patient monitoring software. Information 
on joint replacements was available from 83% of patients while all other variables had 
less than 10% of data missing.  
Percentage of women was 77% while mean age and time from diagnosis were 58.4 
(median, IQR 59.8) and 11.6 (median 7.2, IQR 3.0-17.1) years, respectively. Patients had 
been diagnosed with RA on average at the age of 46.4 (median 47.0, IQR 34.0-58.0). 
Current smokers represented 16% of total population while 95% of patients reported 
having at least basic education. Further information on study participants is reported in 
Table 6.  
The mean number of tender and swollen joints were 1.61 (median 1, IQR 0-2) and 1.37 
(median 0, IQR 0-2), respectively. Rheumatoid factor and anti-CCP-antibodies were 
evident in 70% and 63% of patients, respectively while erosions had been detected 
among 76%. Sixteen per cent of patients reported having undergone a large joint 
replacement surgery in the past. Mean HAQ-DI scores with and without aids and devices 
were 0.87 (median 0.75, IQR 0.13-1.4) and 0.72 (median 0.63, IQR 0.13-1.1), respectively. 
Disease activity as measured with DAS28 ranged from 0.28 to 6.61 (median 2.55) with 
52% and 70% of patients reaching remission and low disease activity, respectively while 
according to the ACR/EULAR 2011 remission criteria the proportions of patients in 
remission were 26% (Boolean) and 28% (SDAI).  
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Table 6. Patient characteristics
1
 (adapted from Aaltonen et al. 2014 [219]) 
 All patients Women Men 
N 890 688  
(77%) 
202  
(23%) 
Age 59.8 (49.6-68.1) 59.0 (48.9-67.2) 62.6 (53.3-71.0) 
Women  77% 100% n/a 
Smoking 16% 15% 20% 
Time from 
diagnosis, years 
7.2 (3.0-17.1) 8.1 (3.1-19.1) 5.1 (2.1-14.1) 
RF+ 69% 67% 77% 
Anti-CCP+ 63% 61% 67% 
Erosions 55% 55% 54% 
TJR
2
  16% 16% 15% 
TJC 28 1 (0-2) 1 (0-2) 0 (0-1.5) 
SJC 28 0 (0-2) 0 (0-2) 0 (0-1) 
CRP 3.0 (1.0-7.0) 3.0 (1.0-7.0) 3.0 (1.0-8.0) 
ESR 9.0 (5.0-19.0) 9.0 (5.0-20.0) 7.0 (3.0-16.0) 
HAQ-DI
4
 0.63 (0.13-1.1) 0.63 (0.25-1.25) 0.25 (0-1.0) 
Inv. global 10.0 (5.0-23.5) 10.0 (5.0-25.0) 10.0 (5.0-20.0) 
Patient global 27.0 (10.0-50.0) 29.0 (10.0-50.0) 23.0 (8.0-45.0) 
Pain 30.0 (10.0-55.0) 30.0 (10.0-55.0) 20.0 (8.0-45.0) 
DAS 28
5
 2.5 (1.7-3.5) 2.6 (1.9-3.6) 2.2 (1.4-3.1) 
DAS28 remission 52% 63% 48% 
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Table 6. (continued) 
 Biologic mono-
therapy 
DMARD+ 
biologic 
DMARD Glucocorticoids 
only 
No anti-
rheumatic 
medication 
N 34  
(4%) 
150  
(17%) 
356 
(74%) 
26 
(3%) 
24 
(3%) 
Age 60.5 (46.4-73.3) 55.3 (48.7-
64.9) 
60.2 (50.4-
68.8) 
67.9 (57.1-72.1) 57.9 (48.5-67.9) 
Women  82% 79% 77% 73% 67% 
Smoking 9% 16% 16% 23% 21% 
Time from 
diagnosis, years 
18.8 (9.1-29.2) 12.1 (8.0-
20.5) 
5.2 (2.1-
14.1) 
23.1 (6.8-38.1) 9.6 (2.9-14.9) 
RF+ 68% 72% 69% 72% 62% 
Anti-CCP+ 59% 66% 63% 60% 48% 
Erosions 78% 81% 48% 63% 27% 
TJR
2
  44% 27% 12% 27% 4% 
TJC 28 0.5 (0-2) 1 (0-3) 1 (0-2) 0 (0-3) 0 (0-1) 
SJC 28 1 (0-2) 1 (0-2) 0 (0-2) 1 (0-3.5) 0 (0-0.75) 
CRP 4.5 (2.7-16.3) 3.0 (1.0-6.5) 3.0 (1.0-
7.0) 
3.9 (1.1-9.5) 2.0 (1.0-6.8) 
ESR 13.0 (7.0-27.3) 11.0 (5.0-
22.5) 
8.0 (5.0-
18.0) 
14.5 (5.0-24.5) 7.0 (5.0-15.8) 
HAQ-DI
4
 1.0 (0.63-1.7) 0.75 (0.25-
1.3) 
0.50 (0-1.1) 1.1 (0-59-1.7) 0.25 (0-1.3) 
Inv. global 16.5 (8.8-30.0) 14.0 (5.0-
25.3) 
10.0 (5.0-
21.0) 
20.0 (5.0-40.0) 2.0 (0-20.0) 
Patient global 46.0 (20.5-70.0) 30.0 (11.0-
57.8) 
25.0 (10.0-
47.0) 
45.5 (30.0-67.0) 7.5 (0-29.8) 
Pain 45.0 (20.0-72.5) 30.0 (12.8-
60.0) 
26.0 (10.0-
50.5) 
47.0 (19.0-75.5) 10.0 (1.00-40.0) 
DAS 28
5
 3.0 (2.5-3.5) 2.7 (1.9-3.7) 2.5 (1.7-
3.4) 
2.9 (2.0-4.5) 2.1 (1.1-2.8) 
DAS28 
remission 
28% 44% 54% 42% 68% 
1
Presented as medians with interquartile ranges 
2
Total Joint Replacement; 
3
mg/l, 
4
Without aids 
and devices, 
5
four variables, ESR; 
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5.2.2 Anti-rheumatic treatment 
DMARDs, glucocorticoids and biologic drugs were being used by 91%, 58% and 21 % of 
patients, respectively while 3.1% were only on glucocorticoids and 2.7% lacked any 
medication. MTX was the most prevalent DMARD (65%) followed by HCQ (49%) and SSZ 
(33%). A triple therapy of aforementioned DMARDs was used by 15%, other MTX-based 
combination by 30%, MTX alone by 20% and other DMARDs alone or in combination by 
26% of patients. Mean weekly dose of methotrexate was 17.7mg (median 20.0, IQR 15.0-
20.0). Mean number of DMARDs per patient was 1.64 (median 2, IQR 1-2).  Complete list 
of DMARDs and biologics used by the study population are shown in Table 7. Oral 
glucocorticoids were used by 512 (58%) with a mean daily prednisolone-equivalent dose 
of 5.6mg (SD 2.8).  
Table 7. Drug utilization (adapted from Aaltonen et al. 2014 [219]) 
Medication Used by (% of total 
patients)) 
DMARDs Used by (% of 
patients) 
Any anti-rheumatic 
medication
1
 
  866 (97%) Methotrexate 579 (65%) 
Synthetic DMARDs   806 (91%) Hydroxychloroquine 439 (49%) 
Biologic drugs   184 (21%) Sulfasalazine 293 (33%) 
Glucocorticoids   512 (58%) Leflunomide 91 (10%) 
Biologic monotherapy    34 (4%) Gold 30 (3%) 
MTX+SSZ+HCQ    88 (15%) Podofyllotoxin 14 (2%) 
  Aazatioprin 10 (1%) 
  Ciklosporin 4 (0%) 
  Myconofenolate 2 (0%) 
  Cyklofosfamide 1 (0%) 
  Chloroquine 1 (0%) 
1
Synthetic DMARDs, biologic drugs and glucocorticoids 
 
Overall, there were 184 biologics users of which 82% were using at least one DMARD 
concomitantly. The most prevalent biologic drugs were etanercept (34%), rituximab 
(19%), adalimumab (16%) and infliximab (11%). Mean time from diagnosis to initiation of 
the first biologic treatment was 11.4 years (median 8.0, IQR 4.0-16.0). Biologic 
monotherapy was most common among the users of anakinra, rituximab, adalimumab 
and golimumab while abatacept was always used in conjunction with DMARDs. In 
addition to current biologics users, 54 patients had been on biologic drugs in the past. 
Thus, overall 30.1% of the cohort had ever been exposed to biologic drugs. 
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Comparison between men and women revealed numerous differences; compared to 
women, men with RA were generally older (62.6 years vs. 59.0 years, p=0.002), had a 
shorter time since diagnosis (5.1 years vs. 8.1 years, p<0.001), were older when 
diagnosed with RA (53.0 years vs. 45.0 years, p<0.001) were more likely to be positive for 
RF (77% vs. 67%, p=0.01) and possibly for anti-CCP as well (69% vs. 61%, p=0.065) (table 
6). The number of tender (p=0.004) and swollen joints (p=0.005) as well as patient self-
assessment of rheumatic activity (29.0 vs. 23.0, p=0.016) were higher among women 
compared to men. Overall, 63% and 48% of men and women were in DAS28 remission, 
respectively.  
Smokers had higher DAS28 score compared to non-smokers (2.8 vs. 2.5, p=0.001) while 
higher education was associated with lower disease activity (2.3 vs. 2.8, p=0.001). RF- and 
anti-CCP status were however similar for smokers and non-smokers alike. Several 
differences were observed in patient and disease characteristics of users of different 
medication regimens (Table 7).  
5.3 Cohort study on the incidence of serious infections and malignancies (III) 
5.3.1 Patients  
Of the 3762 patients included in the study, 2217 and 1545 were identified from ROB-FIN 
and Central Finland Central Hospital, respectively. Of the 4932 medication periods 
included in the study, 1400 were DMARD therapies and 642, 1245, 1207 and 438 
infliximab, etanercept, adalimumab and rituximab therapies, respectively. Disease 
characteristics and the number of prior biologic treatments differed significantly from 
each other at baseline (Table 8). Follow-up took place between 1999 and 2011. 
Altogether, the study medications accumulated 10,994 patient years, lag-time included. 
The median follow-up times in years in DMARD, pooled TNF-inhibitor, infliximab, 
etanercept, adalimumab and rituximab groups were 2.3 (IQR 1.2-2.9), 1.5 (IQR 0.57-3.4), 
1.6 (IQR 0.81-3.4), 1.5 (IQR 0.50-3.5), 1.3 (IQR 0.50-3.4) and 1.1 (IQR 0.50-2.4) while 
corresponding sums of patient-years were 3119, 7163, 1700, 2842, 2620 and 712, 
respectively. The total amount of missing data was 12.4%, ranging from 0 to 26.9% across 
the variables in the dataset. Complete data were available from 58.2% of the included 
patients.  Results of the sensitivity analysis based on  the  complete  cases  were  not 
statistically  different  from  the main results and  data  were  assumed  to  be  missing  at  
random. 
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5.3.2 Serious infections 
Altogether, there were 341 hospitalizations due to infections during the follow-up period, 
of which 61 were subsequent hospitalizations due to the same infection diagnosis (Table 
9). The overall incidence rate of hospitalizations due to all and unique infections were 31 
(CI 95 % 28-34) and 25 (CI 95 % 23-29) per 1,000 patient years, respectively. The most 
frequent infections requiring hospitalization were erysipelas (n=59), infectious 
gastroenteritis and colitis (n=38), bronchitis (n=31), tuberculosis (n=27) and sepsis (n=22).  
There were six hospitalizations due to tuberculosis in the sDMARD group while no 
rituximab treated patient was hospitalized for tuberculosis.  
The counts and crude rates of hospitalizations due to an infection were 106 (IR 34, 95% CI 
28-41), 198 (IR 28, 95% CI (24-32)  53 (IR 31, 95% CI 23-41), 68 (IR 24, 95% CI 19-30), 77 
(IR 29, 95% CI 23-37) and 37 (IR 52, 95% CI 37-72) among the users of sDMARDs, pooled 
TNF-inbitor, infliximab, etanercept, adalimumab and rituximab, respectively. The mean 
length of hospital stay was 7.4 days (SD 5.9) with no statistically significant differences 
between the treatment regimens. In comparison to sDMARDs, results adjusted for age 
and gender showed a statistically significant increase in the incidence for hospital 
admission due to infection for infliximab, adalimumab and rituximab. The full model did 
not however, recognize any single biologic more harmful than sDMARDs. No statistically 
significant differences were observed in direct comparison between TNF-inhibitors and 
rituximab after adjusting for all observed confounders. Sensitivity analysis excluding 
subsequent hospitalizations due to same infections did not statistically significantly alter 
the results (results not shown). From the potential confounders, age, history of previous 
hospitalizations due to infections, HAQ score and use of cortisone predicted increased 
risk for hospitalization due to an infection. Meanwhile, the use of methotrexate and 
sulfasalazine was associated with a reduced infection risk. In the comparison between 
TNF-inhibitors and rituximab, prior biologic drug use was not associated with increased or 
decreased incidence of serious infections.  
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Table 8. Patient characteristics at the beginning of the follow-up (median and interquartile range). 
(adapted from Aaltonen et al. 2014 [220]) 
 sDMARD 
(n=1,400) 
TNF-
inhibitors 
(n=3094) 
Infliximab 
(n=642) 
Etanercept 
(n=1245) 
Adalimuma
b (n=1207) 
Rituximab 
(n=438) 
P-value* 
Age 62 (53-72) 54 (45-61) 52 (44-59) 54 (45-61) 55 (47 -62) 59 (52-67) <0.001 
Gender, female 
(%) 
69% 75% 72% 76% 76% 77% <0.001 
Time from 
diagnosis 
9.4 (5.0-13) 11 (6.0-19) 11 (5.8-17) 11 (5.8-19) 12 (6.4-20) 15 (8.7-23) <0.001 
Year of the 
beginning of the 
follow-up 
2009 
(2008-
2010) 
2006 
(2004-
2008) 
2003 
(2002-
2007) 
2006 
(2004-
2009) 
2006 
(2005-
2008) 
2009 
(2008-
2010) 
<0.001 
RF-positive (%) 65% 78% 78% 77% 78% 88% <0.001 
DAS28 3.2 (2.2-
4.3) 
4.4 (3.2-
5.5) 
4.8 (3.6-
5.8) 
4.2 (3.0-
5.3) 
4.3 (3.2-
5.4) 
4.5 (3.3-
5.4) 
<0.001 
HAQ-DI 0.8 (0.28-
1.4) 
1.0 (0.50-
1.5) 
1.1 (0.62-
1.7) 
1.0 (0.50-
1.5) 
1.0 (0.48-
1.5) 
1.1 (0.6-
1.7) 
<0.001 
Prior malignancy 
(%) 
5.5% 3.2% 3.0% 3.3% 3.3% 10% <0.001 
Hospitalization 
due to an 
infection during 
past 24 months 
(%) 
3.6% 4.0% 4.2% 3.9% 3.9% 7.8% <0.001 
Baseline use of 
methotrexate 
(%) 
75% 54% 54% 54% 56% 41% <0.001 
Baseline use of 
sulfasalazine (%) 
31% 22% 22% 22% 22% 17% <0.001 
Baseline use of 
hydroxychloroqu
ine (%) 
41% 28% 28% 28% 28% 25% <0.001 
Baseline use of 
oral 
corticosteroids 
(%) 
53% 75% 78% 75% 73% 78% <0.001 
Prior Biologic 0% 31% 12% 37% 36% 63% >0.001 
RF=Rheumatoid Factor; HAQ=Health Assessment Questionnaire – Disability Index; DAS28=Disease 
Activity Score based on 28 joint count;  VAS=Visual analogue scale; CRP=C-Reactive Protein  
*Pooled TNF-inhibitor-column excluded from baseline statistical comparison 
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5.3.3 Malignacies 
The number of malignancies during the follow-up was 92, of which 83 were solid cancers 
and 9 hematologic or lymphatic malignancies. The incidence rate of all malignancies was 
8.4 (95% CI 6.7-10) while the rates of solid cancers and hematologic/lymphatic 
malignancies were 7.6 (95% CI 6.0-9.4) and 0.80 (95% CI 0.37-1.6), respectively (Table 9). 
The crude rates of malignancies were highest among the users of sDMARDs (IR 12, 95% CI 
8.6-17) and rituximab (IR 9.5, 95% CI 3.8-20) and lowest among infliximab-treated 
patients (IR 5.8, 95% CI 2.8-11). Analyses adjusted did not reveal any statistically 
significant differences in the incidence rates of malignancies between the users of 
sDMARDs and biologics or between different biologic agents.  
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Table 9. Rates of serious infections and malignancies (adapted from Aaltonen et al. 2014 [220]) 
 sDMARD TNF- 
inhibitors 
Infliximab Etanercept Adalimum
ab 
Rituximab 
Patient years 3119 7162 1700 2842 2620 712 
Serious 
infections 
      
No of 
hospitalization
s 
106 198 53 68 77 37 
Length of 
hospitalization 
in days 
(mean,SD) 
6.3 (3.7) 7.8 (6.7) 9.5 (7.9) 7.3 (5.5) 7.3 (6.7) 7.9 (6.2) 
IR / 1000 
patient years 
34 (28-41) 28 (24-32) 31 (23-41) 24 (19-30) 29 (23-37) 52 (37-72) 
IRR (95% CI) Ref. 0.80 (0.58-
1.1) 
0.89 (0.58-
1.4) 
0.70 (0.47-
1.0) 
0.85 (0.58-
1.3) 
1.5 (0.90-
2.5) 
Adj. IRR * 
(95% CI) 
Ref. 1.4 (1.0-
1.9) 
1.6 (1.1-
2.5) 
1.2 (0.82-
1.8) 
1.4 (0.96-
2.1) 
2.1  (1.3-
3.4) 
Adj. IRR** 
(95% CI) 
Ref. 0.9 (0.6-
1.4) 
1.2 (0.63-
2.3) 
0.84 (0.53-
1.3) 
0.98 (0.60-
1.6) 
1.1 (0.59-
1.9) 
Malignancies       
No of 
malignancies 
39 47 10 21 16 6 
IR / 1000 
patient years 
13 (8.9-17) 6.6 (4.8-
8.7) 
5.9 (2.8-
11) 
7.4 (4.6-
11) 
6.1 (3.5-
9.9) 
8.4 (3.1-
18) 
IRR Ref. 0.52 (0.34-
0.80) 
0.46 (0.23-
0.93) 
0.59 (0.35-
1.0) 
0.49 (0.27-
0.88) 
0.68 (0.29-
1.6) 
Adj. IRR*(95% 
CI) 
Ref. 0.98 (0.61-
1.57) 
0.91 (0.44-
1.9) 
1.1 (0.63-
2.0) 
0.87 (0.47-
1.6) 
1.0 (0.42-
2.4) 
Adj. 
IRR**(95% CI) 
Ref. 1.2 (0.63-
2.2) 
1.2 (0.44-
3.1) 
1.3 (0.65-
2.6) 
1.1 (0.51-
2.2) 
1.2 (0.49-
3.2) 
* Age and gender; **Full model  
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5.4 Cohort study on the incidence of joint replacements (IV)  
5.4.1 Patients 
Overall, 2102 biologics users and 2710 DMARD users were identified from ROB-FIN and 
the Central Finland Central Hospital. There were numerous differences in patient 
characteristics between DMARD and biologics users before matching (Table 10). Biologics 
users were more often females, were younger and had had more joint replacements prior 
to follow-up. Patients in the biologics group also had a longer time from the diagnosis of 
RA to the initiation of follow-up and higher HAQ scores than their DMARD using 
comparators. After PSM, the number of patients was reduced to 1587 in both groups 
while most differences in background data disappeared. Despite matching, small but 
statistically significant differences were observed in HAQ scores and time from RA 
diagnosis. One or more disease activity measurements were missing from 16.0% and 
27.5% of biologics and DMARD users, respectively. 
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Follow-up period in the control group began 4.5 years earlier and ended one year earlier 
compared to biologics users.  The median duration of follow-up periods in the biologics 
and DMARD groups were 3.1 (0.04-10.05) and 8.0 (0.02-12.94), respectively. Thus, 
DMARD group accumulated nearly twice as many patient years as the biologics group did. 
While biologics users had received their first joint replacement 11.2 (median, range -20.1-
52.4) years after the diagnosis, the corresponding time for DMARD users was 14.7 (-6.1-
54.3) years. 
5.4.2 Primary joint replacement operations 
Altogether, 813 primary joint replacements were performed during the follow-up of 
which 550 among the matched population. The number of patients undergoing at least 
one primary joint replacement operation was in 410 (12.9%). The overall incidence rate of 
primary operations per 100 patient years was 2.93 (2.73-3.14). Patients in the biologics 
group had higher incidence rate of joint replacements than the DMARD group in matched 
population (Table 11). While the rates of hip operations were similar, operations of the 
knee and other joints were more common among biologics users. The most common 
indication for joint replacement surgery was RA in both biologics and DMARD groups 
(86% and 79% of operations in matched population, respectively).  The second most 
common reason for operation was primary osteoarthritis in both groups.  
  
57 
 
  
Ta
b
le
 1
1
. N
u
m
b
er
s 
o
f 
jo
in
t 
re
p
la
ce
m
en
t 
o
p
er
at
io
n
s 
in
 t
h
e 
m
at
ch
ed
 p
o
p
u
la
ti
o
n
s 
d
u
ri
n
g 
fo
llo
w
-u
p
 (
ad
ap
te
d
 f
ro
m
 
A
al
to
n
en
 e
t 
al
. 2
0
1
3
 [
2
2
1
])
 
 
Jo
in
t 
re
p
la
ce
m
e
n
ts
 
In
ci
d
e
n
ce
 r
at
e
 p
e
r 
1
0
0
 p
at
ie
n
t 
ye
ar
s 
(9
5
%
 C
I)
1
 
 
B
io
lo
gi
cs
 
sD
M
A
R
D
s 
B
io
lo
gi
cs
 
sD
M
A
R
D
s 
P
ri
m
ar
y 
o
p
e
ra
ti
o
n
s 
2
4
0
  
3
1
0
 
3
.9
0
 (
3
.4
2
-4
.4
3
) 
2
.6
4
 (
2
.3
5
-2
.9
5
) 
   
H
ip
 
5
8
 (
2
4
.2
%
) 
1
0
5
 (
3
3
.9
%
) 
0
.9
4
 (
0
.7
2
-1
.2
2
) 
0
.8
9
 (
0
.7
3
-1
.0
8
) 
   
K
n
ee
 
1
0
1
 (
4
2
.1
%
) 
1
3
1
 (
4
2
.3
%
) 
1
.6
4
 (
1
.3
4
-2
.0
0
) 
1
.1
1
 (
0
.9
3
-1
.3
2
) 
   
O
th
er
 jo
in
ts
 
8
1
 (
3
3
.8
%
) 
7
4
 (
2
3
.9
%
) 
1
.3
2
 (
1
.0
5
-1
.6
4
) 
0
.6
3
 (
0
.4
9
-0
.7
9
) 
R
e
as
o
n
 f
o
r 
p
ri
m
ar
y 
o
p
e
ra
ti
o
n
 
   
R
h
eu
m
at
o
id
 a
rt
h
ri
ti
s 
2
0
6
 (
8
5
.8
%
) 
2
4
6
 (
7
9
.4
%
) 
3
.3
5
 (
2
.9
1
-3
.8
4
) 
2
.0
9
 (
1
.8
4
-2
.3
7
) 
   
O
th
er
 a
rt
h
ri
ti
s 
0
 
1
 (
0
.3
%
) 
0
.0
0
 (
0
.0
0
-0
.0
6
) 
0
.0
1
 (
0
.0
0
-0
.0
5
) 
   
P
ri
m
ar
y 
o
st
eo
ar
th
ri
ti
s 
2
8
 (
1
1
.7
%
) 
4
7
 (
1
5
.2
%
) 
0
.4
6
 (
0
.3
0
-0
.6
6
) 
0
.4
0
 (
0
.2
9
-0
.5
3
) 
   
Se
co
n
d
ar
y 
o
st
eo
ar
th
ri
ti
s 
4
 (
1
.7
%
) 
0
 
0
.0
7
 (
0
.0
2
-0
.1
7
) 
0
.0
0
 (
0
.0
0
-0
.0
3
) 
   
O
th
er
 r
ea
so
n
  
2
 (
0
.8
%
) 
1
6
 (
5
.2
%
) 
0
.0
3
 (
0
.0
0
-0
.1
2
) 
0
.1
4
 (
0
.0
8
-0
.2
2
) 
R
e
vi
si
o
n
 o
p
e
ra
ti
o
n
s 
4
0
 
9
8
 
0
.6
5
 (
0
.4
6
-0
.8
9
) 
0
.8
3
 (
0
.6
8
-1
.0
2
) 
   
H
ip
 
1
7
 (
4
2
.5
%
) 
5
9
 (
6
0
.2
%
) 
0
.2
8
 (
0
.1
6
-0
.4
4
) 
0
.5
0
 (
0
.3
8
-0
.6
5
) 
   
K
n
ee
 
7
 (
1
7
.5
%
) 
2
5
 (
2
5
.5
%
) 
0
.1
1
 (
0
.0
5
-0
.2
3
) 
0
.2
1
 (
0
.1
4
-0
.3
1
) 
   
O
th
er
 jo
in
ts
 
1
6
 (
4
0
.0
%
) 
1
4
 (
1
4
.3
%
) 
0
.2
6
 (
0
.1
5
-0
.4
2
) 
0
.1
2
 (
0
.0
6
-0
.2
0
) 
R
e
as
o
n
 f
o
r 
th
e
 r
e
vi
si
o
n
 
   
Lo
o
se
n
in
g 
8
 (
2
0
.0
%
) 
1
7
 (
1
7
.3
%
) 
0
.1
3
 (
0
.0
6
-0
.2
6
) 
0
.1
4
 (
0
.0
8
-0
.2
3
) 
   
In
fe
ct
io
n
 
6
 (
1
5
.0
%
) 
1
2
 (
1
2
.2
%
) 
0
.0
3
 (
0
.0
0
-0
.1
2
) 
0
.1
0
 (
0
.0
5
-0
.1
8
) 
   
O
th
er
 r
ea
so
n
 o
r 
m
is
si
n
g 
2
6
 (
6
5
%
) 
6
9
 (
7
0
.4
%
) 
0
.4
2
 (
0
.2
8
-0
.6
2
) 
0
.5
9
 (
0
.4
6
-0
.7
4
) 
1 P
o
is
so
n
 d
is
tr
ib
u
ti
o
n
 
 
58 
Survival analysis of the proportion of patients undergoing primary joint replacement 
operation during the follow-up time reveals a statistically significant difference 
considering small joint operations (Figure 6). However, survival without any hip or knee 
operations during the follow-up was similar.  
 
Figure 6. Kaplan–Meier survival plots indicating the percentage of patients without joint 
replacements  to either (A) hip and knee or (B) other joints during the follow-up (Aaltonen et al. 
2013 [221]). 
 
5.4.3 Revision operations 
Primary operations performed within follow-up in matched and unmatched populations 
were revised in 67 (8.4%) and 31 (5.7%) cases, respectively. The incidence rate of 
revisions appeared lower in the biologics (0.65, 0.46-0.88) group than in the DMARD 
group (0.83, 0.68-1.01) (Table 11). The difference was mostly due to lower rates of hip 
and knee revisions (although there were no statistically significant differences) and in the 
rate of other joint revisions the situation was the opposite. There were no statistically 
significant differences between biologics and DMARD users in reasons for revision.   
The survival of the joints replaced prior to follow-up appeared similar in the biologics 
group compared to DMARD users both in hip and knee (p=0.450) and other joints 
(p=0.571) (Figure 7).  The primary surgery had taken place 5.2 (median, range 0.1-25.0) 
and 5.3 (0.01-22.1) years before the follow-up in biologics and DMARD groups with no 
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statistical difference (p=0.924), respectively. The results for prostheses installed during 
follow-up suggested that while the biologics users might have better survival of hip and 
knee joint replacements (p=0.236), the situation was reversed regarding other joints 
(p=0.278) (Figure 8).   
 
Figure 7. Survival without revisions in joint replacements either to (A) hip and knee or (B) other 
joints installed prior to follow-up (Aaltonen et al. 2013 [221]). 
 
Figure 8. Survival without revisions in joint replacements either to (A) hip and knee or (B) other 
joints installed during follow-up (Aaltonen et al. 2013 [221]). 
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5.4.4 Sensitivity analyses 
There were no statistically significant differences between the rates of primary operations 
between the biologics users identified from ROB-FIN or Central Finland Central Hospital. 
Biologics users with follow-up longer than 9.5 years have lower incidence rate of primary 
operations (2.27, 95% CI 1.61–3.12) compared to un-stratified results, which was not the 
case among sDMARD treated patients (2.72, 95% CI 2.32–3.13). Patients with missing 
data had shorter follow-up times compared to patients with complete data. Biologic users 
with missing data had a higher incidence rate of operations compared to complete cases, 
but only accounted for 8.1% of the patient years. 
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6 DISCUSSION 
6.1 General discussion 
The studies included in this thesis evaluated the efficacy, safety, outcomes and utilization 
of biologic DMARDs in the treatment of RA. Firstly, we identified, evaluated and pooled 
all relevant RCTs on the efficacy and safety of TNF-inhibitors in treatment of RA. Secondly, 
a cross-sectional overview was performed to describe the disease characteristics and 
medical treatment of prevalent RA patients in Finnish outpatient specialized healthcare. 
Thirdly, we executed two cohort studies comparing the incidence of joint replacement 
surgery, serious infections and malignancies between the users of biologic and synthetic 
DMARDs. The results of our studies aim at strengthening the existing knowledge of the 
biological DMARDs as a treatment alternative in RA, especially within the Finnish 
healthcare environment.  
6.2 Data collection and methods 
6.2.1 Systematic review (I) 
Systematic review is a method of research narrating all empirical evidence on subject 
with well-defined eligibility criteria and research question [155].  It features thoroughly 
documented and reproducible methodology aimed to identify, select and evaluate all 
relevant previously published data. Many systematic reviews contain meta-analyses, 
which are statistical methods to summarize the results of the independent studies. To 
date, only two major RCTs comparing biologic drugs to one another have been performed 
[222]. Undertaking a systematic review and a meta-analysis allowed us to indirectly 
compare the efficacy and safety of all five TNF-inhibitors available at the time. The 
literature search was designed for sensitivity rather that specificity and as a consequence, 
we identified over 5454 references, of which 3841 were manually evaluated by two 
persons by title and abstract. Subsequently, 76 potentially relevant full-text articles were 
evaluated for inclusion. Forty publications reporting of 26 RCTs were included with 6780 
and 3082 patients in intervention and control groups, respectively.  As the study featured 
studies with different TNF-inhibitors and comparators, several subgroup analyses were 
undertaken. Some heterogeneity in the results of the included RCTs was present and as a 
result, random effects model was used in the meta-analyses.  
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6.2.2 Cross-sectional study (II) 
Studies on RA often focus on a particular subgroup defined by a distinct condition or 
treatment. Cross-sectional study on the other hand, is a study which includes all persons 
in the population, or a representative sample of all such persons, selected without regard 
to exposure or disease status [223].  Cross-sectional studies have been performed in 
Finland, but not on a nation-wide scale [224]. We invited Finnish outpatient specialized 
healthcare clinics to enroll consecutive patients with the aim of reaching a representative 
sample of 1000 patients with RA. A purpose-made data collection form was used 
comprising questions on the patients’ disease characteristics, medical treatment and 
socioeconomic factors. The questionnaire featured several scores and indices such as 
DAS28, SDAI and CDAI with the aim of promoting their use in routine healthcare. One of 
the clinics participating in the study used an electronic patient monitoring software to 
collect the data instead of paper data collection forms. However, the same variables were 
collected and the same inclusion criteria for patients were employed in clinics utilizing 
either manual or electronic data collection. 
6.2.3 Cohort studies (III and IV) 
Several studies have compared the inclusion criteria of major RCTs and the characteristics 
of RA patients using biologic drugs in routine clinical practice and found that only a small 
subset of RA patients would have been eligible for those trials, limiting their 
generalizability  [12,225]. Furthermore, the relatively short follow-up times and limited 
number of included patients may be insufficient to reveal rare, delayed or long-term 
outcomes. Therefore, observational research based on large cohorts of true users with 
long exposure times can supplement the information provided by RCTs. Also, RCT studies 
are very costly and in some cases unethical whereas most observational studies require 
less resources and study personnel to perform. Many countries, especially Nordic 
countries, have healthcare registers with mandatory data collection, facilitating good 
quality retrospective register studies. Following the introduction of TNF-inhibitors to 
clinical use, rheumatologists in European countries established prospective cohort studies 
to monitor the safety and effectiveness of the new therapies [226]. The Finnish biologics 
register, namely the national register for biologic treatment in Finland (ROB-FIN) was 
founded by the Finnish Society of Rheumatology and includes patient data from 1999 
onwards. Inclusion to ROB-FIN required patients’ informed consent and was voluntary for 
the rheumatologist. Coverage has been estimated to be 60% of all RA patients treated 
with bDMARDs in Finland [227]. 
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Our cohort studies were based on a mixture of prospectively and retrospectively collected 
data. The patients included in our cohort studies were identified from three sources; 
ROB-FIN, hospital records of the Central Finland and an annual survey-based time-series 
performed in the Jyväskylä region. The survey data was used to extend the length of the 
follow-up in study IV as it was deemed necessary considering the delayed nature and low 
incidence of the joint replacement operations. Information entry to the national registries 
for hospitalizations, malignancies and joint replacement operations is mandatory in 
Finland thus providing an unbiased source for medical outcomes.  The data on 
malignancies dates back to 1953 and has been shown to be complete in solid tumors and 
near-complete in lymphatic malignancies [228]. Patients with history of malignancies 
were included in the study, but only four recurrent malignancies were observed.  Also, 
information on prior malignancies, serious infections during the past 24 months and prior 
joint replacement operations were used as confounders in the multivariate analyses, 
which were undertaken to account for the differences between sDMARD and biologic 
drug users either by providing adjusted IRRs or for the purposes of matching. In study IV, 
biologic drug users were pooled to increase statistical power due to the low incidence of 
joint replacement operations while in study III the users of infliximab, etanercept, 
adalimumab and rituximab were analyzed separately. 
6.3 Efficacy of the biologic DMARDs in the treatment of RA 
Our systematic review (I) confirmed that as a group, TNF-inhibitors are more efficacious 
than comparator treatments in general. However, stratification of the trials by the choice 
of comparator and the use of concomitant MTX has significant impact on the effect size.  
Without concomitant MTX treatment, TNF-inhibitors are more efficacious than placebo 
but equal to MTX. The combination of TNF-inhibitor and MTX is however, superior to 
monotherapy with either TNF-inhibitor or MTX. Prior exposure to MTX increased the 
observed difference between TNF-inhibitor and MTX groups, suggesting that treatment 
with bDMARDs is more efficacious among patients with insufficient treatment response 
to MTX as compared to MTX-naïve patients.  Differences in the RRs for reaching the 
treatment response between individual TNF-inhibitors are subtle, but according to our 
results infliximab and golimumab are not associated with statistically significantly 
improved treatment response over the comparator. The apparent lack of response might 
however, be explained by insufficient statistical power and heterogeneity in the inclusion 
and exclusion criteria as compared to studies of other TNF-inhibitors. Increased doses of 
TNF-inhibitors were not associated with improved treatment response in comparison to 
normal doses.  
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A previous systematic review and meta-analysis pooled efficacy results from different 
time points and found slightly different estimates for the efficacy of TNF-inhibitors, which 
is likely due to differences in the methodology of the systematic reviews and meta-
analyses [229]. Also several large clinical trials have been published since the 
aforementioned review along with the introduction of two novel TNF-inhibitors, 
certolizumab pegol and golimumab. More recently, Nam et al. performed a systematic 
review including all biologic DMARDs, focusing solely on the efficacy measured by 
reaching ACR 70 response [230]. Besides confirming our results on the effect of prior MTX 
treatment on the efficacy of TNF-inhibitors, they also found that the differences between 
individual bDMARDs are subtle. In head-to-head studies of bDMARDs, the combination of 
abatacept and MTX was similar in efficacy as the combination of adalimumab and MTX, 
yet monotherapy of tocilizumab was more efficacious as compared to monotherapy of 
adalimumab  [20,231]. Several studies were found by Nam et al., which explored the 
possibility of discontinuing the treatment or alternatively, reducing the dosage of TNF-
inhibitor after the initial treatment response had been achieved [230]. Although the 
maintenance of low disease activity is better with bDMARD continuation at full dose, high 
drug expenditures warrant further research to disclose if early treat-to-target approach 
and subsequent drug discontinuation or dose reduction would be cost-effective. 
Regarding the similar efficacy of increased dose of TNF-inhibitors compared to normal 
doses, another previous systematic review reached the same conclusion as we did [22]. 
Lately, several studies have compared treatment with the combination of bDMARDs and 
sDMARDs to intensified treatment with sDMARDs, in most cases the triple therapy 
consisting of MTX, SSZ and HCQ [230]. Most such studies have found both equal in clinical 
efficacy with radiographic progression possibly better delayed by the bDMARD 
[15,16,109]. In accordance with our results, Nam et al. found that the combination of 
bDMARD and sDMARD is more efficacious in comparison to monotherapy of bDMARD, 
except possibly among the patients with prior incomplete treatment response to MTX 
[230]. 
A biosimilar infliximab authorized by EMA for treatment of RA, CT-P13 was directly 
compared against innovator infliximab [232]. A RCT with more than 600 patients was 
unable to show any statistically significant differences between the efficacy of the 
innovator and the biosimilar infliximab, measured as ACR20 response at 30 weeks. Similar 
findings were seen among patients with ankylosing spondylitis, as well [233]. This implies 
that the results of our systematic review are generalizable to the currently available and 
probably also to upcoming biosimilar DMARDs. Further research is however, warranted.   
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Owing to the stringent inclusion criteria for RCTs, the results of the randomized clinical 
trials may no be fully generalizable to routine care. In European countries, the proportion 
of patients starting their first biologic eligible for RCTs has ranged from 21 to 79 per cent 
[12,234,235]. Observational trials have shown that majority of the patients treated with 
bDMARDs in routine care benefit from the treatment with the RCT eligible patients having 
superior effectiveness results in comparison to those not eligible. In accordance to our 
systematic review based on RCTs, no TNF-inhibitor has been deemed superior to other in 
studies based on observational data [111–114]. Opinions and results on whether the cost-
effectiveness results based on modelling studies utilizing data from RCTs are 
generalizable to routine case are not coherent [235–237]. Generalization of results 
derived from RCTs to routine clinical practice might be further hindered by high 
percentages of patients switching between treatment arms, often from placebo to active 
treatment owing to the lack of treatment response. As the results are often reported 
using intention-to-treat protocol, the true length of exposure among placebo-treated 
patients might be less than among patients treated with active treatment. On the other 
hand, a high incidence of adverse events in the active treatment group might lead to 
opposite results.  
The current treatment guidelines by EULAR suggest commencing the treatment of a 
recent RA with MTX or a combination of sDMARDs in addition to low-dose glucocorticoids 
[8]. Biologic drugs including TNF-inhibitors, toclizumab, abatacept and rituximab in 
certain conditions are recommended for patients with incomplete response to sDMARDs. 
In the light of our findings of biologic drugs being more efficacious among patients with 
incomplete response to MTX as compared to MTX naive patients, the EULAR 
recommendation on starting treatment with sDMARDs seems justified. We found that 
there are only few differences between TNF-inhibitors in efficacy and consequently, the 
guidelines do not raise any single substance over another. Moreover, they consider 
tocilizumab, abatacept and even rituximab as plausible alternatives as the patients’ first 
biologic treatment, the conclusions of which   are mainly based on the recent systematic 
review by Nam et al. [230].  
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6.4 Disease characteristics and the use of biologic and synthetic DMARDs in treatment of 
RA in Finland 
6.4.1 Disease characteristics 
A cross-sectional (II) study aimed to provide a nationwide overview on patients with RA in 
Finland; the RAMI project included consecutive patients from participating clinics, 
covering information on patient background, disease activity and medical treatment. The 
included patients had a median age of 59.8 years while 23% were men, which are similar 
as described in previous studies [224,238,239]. The included cohort had a median DAS28 
value of 2.55 with 52% and 70% of patients reaching remission and low disease activity, 
respectively. An international cross-sectional study published in 2007 included also three 
clinics from Finland whose patients had a median DAS28 of 3.1 [224]. Therefore, it could 
be postulated that the average disease activity of prevalent RA cases has decreased 
during the past six years. In contrast however, the median disease activity of sDMARD 
users included in the cohort studies was higher than either in ours or in the previous 
cross-sectional study [224].  
The median DAS28 at the baseline of TNF-inhibitor treatment among the patients 
included in the cohort study on serious infections and malignancies (III) was 4.4 (IQR 3.2-
5.5), which as expected, was higher as compared to that of prevalent biologic drug users 
within the cross-sectional study (II). While the median HAQ score at the baseline of TNF-
inhibitor treatment in the cohort study (III) was 1.0, the corresponding score varied 
between 1.25 and 1.88 among the RCTs included in the systematic review (I).  This implies 
that the patients included in the RCTs have a more severe RA as compared those treated 
in routine healthcare, which has been documented in other countries as well [12]. 
In the cross-sectional RAMI study (II), remission rates based on the ACR/EULAR criteria 
differed significantly from those based on DAS28 score, confirming that the former are 
more stringent than the latter [240].  We found a significant difference between patient 
and investigator global assessments, which might be due to physicians and patients 
focusing on different aspects of the disease in their respective evaluations [241]. Tobacco 
smoking is an environmental factor contributing to the severity of rheumatoid arthritis 
and we found in our study that tobacco-smokers have a higher disease activity compared 
to non-smokers [242,243]. However, a prior international study found an opposite trend, 
which might suggest that the effect of smoking on disease activity is confounded by other 
factors such as socioeconomic status and drug adherence [244]. In 2011, 22% and 15% of 
Finnish inhabitants men and women aged between 15 and 64 were current smokers, 
respectively [245]. As the corresponding percentages in study II were found to be 20% 
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and 15%, respectively it is plausible to assume that the smoking habits of RA patients do 
not significantly differ from those of the general population. 
According to the results of study II, men are older than women when diagnosed with RA, 
which is in accordance with the previous evidence on later onset of RA among men 
[246,247]. RF was evident in 77% and 67% of men and women, respectively. Differences 
between sexes in both in time from diagnosis and RF status might be different underlying 
pathological processes of RA [38,46]. Women also have a more active disease as 
compared to men, yet with similar erosive progression. Controversially, biologic 
treatments had been initiated earlier for men in comparison to women. 
6.4.2 Medical treatment 
Overall penetration of disease-modifying anti-rheumatic therapies observed in the cross-
sectional study (II) was very high, considering that recent Swedish study identified only 
76% of RA patients as current or past users of anti-rheumatic medication [239]. A 
previous cross-sectional study does nevertheless, support our results [224]. The 
inconclusive results may be explained to some extent by the different study designs and 
different methods for identifying the included RA patients. MTX was the most commonly 
used sDMARD followed by HCQ and SSZ in both our studies II and III as well as in prior 
studies [224]. The RACo-combination was used by 15% of the patients in study II while 
58% of the patients were currently using oral glucocorticoids. Any biologic treatments 
were used by 21% of the patients, which is twice as high as in the year 2006 [224]. The 
use of bDMARDs varies greatly between countries. However, as shown by Sokka et al., 
prevalent disease activity does not necessarily correlate with high penetration of biologic 
treatments [224,248]. The apparent lack of correlation may however, be confounded by 
unmeasured differences in the severity of the disease. Instead,  prevalent disease activity 
is clearly associated with the gross domestic product of the country, but whether this 
effect is mediated via low access to treatment or other factors such as low socioeconomic 
status is unclear [249]. According to the results of study II, the first biologic treatment was 
initiated 8 years after the diagnosis while the time from diagnosis to the baseline of the 
first TNF-blocker in study III was 11 years. Studies from other countries are more in line 
with the former, but it should be taken into account that the data collection for study II 
took place between 2011 and 2012 while the data for the cohort studies ranges from 
1999 to 2011 [112,113]. 
Study II showed that the patients on biologic monotherapy had a higher DAS28 and HAQ 
scores compared to patients on sDMARDs or combination of biologics and sDMARDs. 
Also, the patients on biologic monotherapy had the longest time since diagnosis, which 
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could mean that all possible sDMARDs have already been tried and subsequently 
discontinued and hence, biologic monotherapy would have been used as a last resort. 
Biologic monotherapy was most common among the users of anakinra, rituximab and 
adalimumab. However, the low number of anakinra-treated patients limits the 
generalizability of the finding.   Although the authorization details of infliximab call for 
concomitant MTX treatment, 15 per cent of the infliximab users had no ongoing 
concomitant sDMARD therapy. In study III, only 54% of infliximab users were on MTX at 
baseline. Lack of concomitant sDMARD therapy among infliximab-treated patients may be 
suboptimal since concomitant use of MTX has been shown to reduce the risk of 
treatment discontinuation, probable owing to the prevention of anti-drug antibody 
formation [74,113]. Controversially, the patients on no ongoing active antirheumatic 
medication had the lowest disease activity of all medication strategies. This finding is not 
clearly explained by the data, but one could speculate that these patients had been 
treated to remission or low disease activity with prior treat-to-target medication strategy 
or alternatively, some of the patients included in this group could be pregnant.   
Based on our results it is not possible to evaluate if Finnish and European treatment 
guidelines have been followed since we do not have data on the prior treatment and 
medical history [7,8]. Of the rituximab users included in the study III, 37% had not been 
treated previously with prior bDMARDs. Although the most recent EULAR guidelines 
warrant the use of rituximab as the first choice for biologic treatment under certain 
conditions, the data for the study has been collected prior to the publication of the latest 
iteration of the guidelines. Rituximab users had a greater percentage of prior serious 
infections and malignancies compared to TNF-treated patients and rituximab could have 
been considered a safer alternative in presence of aforementioned medical history.  
6.5 Safety and outcomes of biologic DMARDs in treatment of RA 
6.5.1 Discontinuation due to adverse events 
The results of our systematic review (I) revealed TNF-inhibitors as a group equal to 
comparator treatment in terms of discontinuations due to adverse events, which was 
already noted by a previous study [22]. A subgroup analysis however, revealed that TNF-
inhibitors in combination with MTX were associated with increased risk for 
discontinuation owing to adverse events in comparison to MTX alone (RR 1.37 95% CI 
1.01-1.87). On the other hand, a comparison between TNF-inhibitor monotherapy and 
placebo failed to show statistical significance despite a strong trend (RR 1.90, 95% CI 0.94-
3.84), possibly due to the heterogeneity between the included studies. Safety of TNF-
inhibitor and MTX were similar with a weak trend favoring the former. There were some 
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differences between individual agents. Etanercept was associated with reduced likelihood 
to discontinue treatment due to adverse events while infliximab, adalimumab and 
certolizumab pegol  were associated with more discontinuations  than the comparator, 
which is in accordance to results of previous systematic reviews [21,22]. Elevated dosing 
of TNF-inhibitors was comparable to normal dosing in terms of discontinuations due to 
adverse events (RR 0.98 95% CI 0.72-1.35). However, the proportion of patients 
experiencing any adverse event was statistically significantly lower among the patients 
treated with higher than normal doses. In a Danish observational study, 9% and 17% of 
patients discontinued TNF-inhibitor treatment within 6 and 48 months after the 
treatment onset owing to adverse events, respectively with no statistically significant 
differences observed between infliximab, etanercept and adalimumab in adjusted 
survival analysis [112].  
6.5.2 Injection and infusion reactions 
As a group, TNF-inhibitors increased the risk for injection or infusion reactions (RR 2.46, 
95% CI 1.63-3.70). The risk of experiencing an infusion reaction following the 
administration of infliximab was lower among the elevated dosing group, which might be 
due to greater immunosuppressive effect and subsequently reduced immunogenicity. 
However, there was considerable heterogeneity in the relative risk for injection or 
infusion reactions, hindering any conclusions based on subgroup analyses. 
6.5.3 Serious infections 
In our cohort study (III), the crude incidence rate of serious infections per 1000 patient 
years among the TNF-inhibitor users was 28 (95% CI 24-32) while the corresponding 
incidence rates in previous studies have ranged from 26 to 55 [24,128,131]. The 
comparison of results based on observational studies from different may however, be 
thwarted by the differences in the definition of serious infections, selection of study 
participants and study methodology. Twenty-Seven cases of tuberculosis were observed 
of which most among TNF-inhibitor-treated patients and none among rituximab users. As 
TNF-inhibitors are known to predispose to reactivation of latent tuberculosis, tuberculosis 
is nowadays screened for and treated if necessary, before commencing the biologic anti-
rheumatic treatment [250].  
Etanercept and infliximab users had the lowest (IRR 0.84 95% CI 0.53-1.3) and the highest 
(IRR 1.2 95% CI 0.63-2.3) incidence rate ratios for serious infections in comparison with 
sDMARDs, respectively although these differences were not statistically significant. 
Rituximab was comparable in terms of the incidence of serious infections to both TNF-
inhibitors and sDMARDs. Some of the patients included in the study III experienced 
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multiple episodes of hospitalizations due to infections. British guidelines suggest that 
treatment with TNF-inhibitors should be discontinued in the presence of serious 
infections, but may be commenced again once the infection has resolved [251]. 
Subsequent hospitalizations due to same infection diagnosis could be correlated and thus 
in violation of Poisson distribution and therefore, we performed a sensitivity analysis by 
excluding multiple hospitalizations due to same infection. This did not however, change 
the results in a significant manner (data not shown). Length of the hospital stay was not 
statistically significantly different between the users of sDMARDs, TNF-inhibitors or 
rituximab, which suggest that the severity of infections was similar among the treatment 
groups and that there was no subsequent tendency to hospitalize the users of either 
group more easily, given that the physician was aware of the patients’ exposure to 
immunosuppressive treatments. Post-operative infections were excluded from study III 
due to a dissimilar rate of arthoplastic surgery among DMARD and biologics users in 
Finland, which could have biased the results [221]. However, the study IV revealed no 
statistically differences in the incidence of post-operative infections following a joint 
replacement operation.  
The systematic review (I) showed a risk for serious infections between TNF-inhibitor and 
comparator groups (RR 1.40 95% 0.93-2.10) to be statistically insignificant although a 
slight trend towards increased risk was evident. Our cohort study (III), however, found no 
such trend after adjusting for confounding (IRR 0.9 95% CI 0.6-1.4) while previous 
observational cohort studies identified by a systematic review by Ramiro et al. have 
acquired adjusted estimates ranging from 1.1 to 2.4 [24,128,133]. Our adjusted estimates 
for IRR are nevertheless, within the 95% confidence intervals of previous studies. Also, 
the choice of variables included in the model as confounders plays a major role as 
evidenced by study III.  Adjustment for age and sex only produced statistically significant 
IRRs for infliximab and rituximab in comparison to sDMARD users. The same pattern was 
previously observed by Dixon et al, highlighting the importance of clinical data on disease 
characteristics of the patients [252]. Although eight previous observational studies on the 
incidence of serious infections during exposure to TNF-inhibitors were identified by a 
systematic review, a meta-analysis was not warranted given the heterogeneity of the 
included studies [24]. 
The increased risk for serious infections among TNF-inhibitor users in comparison to 
sDMARD-treated patients has been observed to be highest during the first six months of 
treatment onset [123]. This might be partially so because the TNF-treated patients 
susceptible to infections were excluded from the analysis after their first outcome, 
enriching the remaining population with more infection-resistant patients. Patients 
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treated with sDMARDs, on the other hand, have been taking those drugs for a period of 
time and the infection-susceptible patients may have discontinued their use prior to  
follow-up [253]. The so called prevalent-user bias may be evidenced by MTX and SSZ 
being statistically significantly associated with decreased incidence of serious infections in 
our study III. Concomitant use of oral glucocorticoids, history of serious infections, age 
and HAQ score were statistically significant confounders for increased incidence of 
infections. We did not include the daily dose glucocorticoids in our statistical model, but a 
previous study found a dose-dependence between the use of glucocorticoids and the 
incidence of serious infections [132].  
6.5.4 Malignancies 
The  crude  rates  of malignancies  were  highest  among  the  users  of  sDMARDs  and  
rituximab  and  lowest  among  infliximab-treated  patients, but adjusted results proved 
this finding to be confounded. As a group, TNF-inhibitors were not associated with 
elevated risk for malignancies (IRR 1.2 95% CI 0.44-3.1). Previous studies have found 
similar or even lower estimates, confirming that TNF-inhibitors are unlikely to predispose 
to malignancies in general [24,139,142–144]. The risk of melanoma and non-melanoma 
skin cancer may be increased in patients on TNF-inhibitors, but we were unable to 
confirm that in our analyses [24]. Only 9 hematologic or lymphatic malignancies were 
observed, preventing any multivariate analyses. Prior results have, however, concluded 
that high disease activity and not the exposure to TNF-inhibitor treatment is associated 
with increased incidence of lymphatic malignancies [136].  
6.5.5 Joint replacements 
The cohort study on joint replacement surgery comprised 813 primary and 204 revision 
operations among 4812 patients, accumulating a total of 27744 patient years. After the 
matching, 240 (IR 3.90 95% CI 3.42-4.43) and 310 (IR 2.64 CI 95% 2.35-2.95) primary 
operations remained among the biologic and synthetic DMARD users, respectively.  The 
higher incidence of primary operations among the biologic DMARD users compared to 
sDMARD users was not expected and conflicts with some of the prior reports [17,34]. 
More recently in a Spanish observational study however, Leon et al. showed incidences 
rates of 3.1 and 2.35 total joint replacement operations per 100 patient years among the 
users and nonusers of biologic treatments, respectively, yielding an adjusted odds ratio of 
1.95 (95% CI 1.01-3.86) [254]. The annual number of primary joint replacement 
operations performed due to RA has declined over the past 15 years in Finland, but this 
does not explain our results since the follow-up of biologics took place later as compared 
to sDMARD users [35]. It may be that the matching in cohort study (IV) failed to account 
72 
for the underlying differences in disease severity and erosive progression between the 
biologic and synthetic DMARD users. Furthermore, while biologic drugs have been shown 
to reduce or delay the erosive progression, they do not reverse the damage already 
occurred [230]. Previous studies have shown that the patients’ first total joint 
replacement operations takes place in average eight years after the diagnosis while the 
corresponding median time in our study was 11 and 15 years for the users of biologic and 
synthetic DMARDs, respectively  [31,254]. Coincidently, study III showed that the 
patients’ first biologic treatment was also commenced 11 years after the date of 
diagnosis. Therefore, from the perspective of preventing erosive progression and 
subsequently reducing the need for joint replacement surgery, it could be beneficial to 
initiate biologic treatment earlier in the course of RA as is currently recommended [7,8]. 
Whether this would be cost-effective is unclear and given the currently available 
evidence, any cost-effectiveness models on the subject would inevitably feature a 
considerable amount of uncertainty. 
The incidence rate of revision operations was slightly higher among cDMARD users (IR 
0.83 95% CI 0.68-1.02) as compared to biologic drugs users (IR 0.65 95% CI 0.46-0.89). The 
survival analyses on the need to perform a revision to a specific joint replacement 
installed prior to or during the follow-up period revealed no statistically significant 
differences. However, there was a trend favoring the bDMARD users and the plausible 
improvement in survival of prostheses would be in line with the reduced incidence rate of 
revision operations. The incidence rate of post-operative infections was similar between 
the treatment alternatives although it has been suspected that not all cases have been 
reported to FAR [255]. 
The pathologic process leading to aseptic loosening is largely driven by wear debris from 
the prosthesis, especially among patients with RA [149,256]. Also tumor necrosis factor 
alpha is involved in the process and it is suggested that bDMARDs could slow down the 
osteolytic process. Despite the lack of statistically significant difference in the incidence 
rate of revisions and survival stratified by joints, there was a tendency indicating that 
knee and hip revisions would be less common among biologic vs. synthetic DMARD users 
while the situation was reversed regarding other joints (Figure 8). The higher revision rate 
in cDMARD group compared to biologic drug users could perhaps reflect greater bone 
destruction or poorer bone quality at the time of primary surgery. However, owing to the 
role of inflammatory cytokines, such as TNF-α, in aseptic loosening and because they 
stimulate osteoclast activity, it could be speculated that the lower revision rates in the 
biologic users might be due to inhibition of the chronic foreign body inflammation 
(particle disease).  
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6.6 Limitations of the study  
6.6.1 Limitations of the systematic review (I) 
Our systematic review features several limitations that need to be taken into account 
when evaluating the implications of the results. The efficacy and safety results pooled in 
the meta-analysis derive from RCTs, which have been conducted as multi-center studies 
globally and may therefore not be directly generalizable to Finnish healthcare. The 
generalizability of the results may be further hampered by the stringent inclusion criteria, 
which often exclude patients with co-morbidities and prior biologic treatments [12,218]. 
Some of the studies included in the systematic review neglected to report the efficacy 
and safety results at all relevant time-points such as 3, 6 and 12 months after treatment 
onset despite sufficient trial length, resulting in decreased statistical power. We could 
have addressed this by contacting the authors of the original publications for unpublished 
data, but were unable to do so within the time constrain. Indirect comparison of TNF-
blockers may be biased due to differences in the inclusion criteria, year of publication and 
the choice of comparator. We excluded all non-randomized studies as a classical 
frequentistic meta-analysis would probably not have been suitable to pool their results 
and hence, possibly ignored some information on the effectiveness and safety of TNF-
inhibitors. A Bayesian meta-analysis with meta-regression on the other hand, could have 
addressed for the between-study differences and incorporated information from 
observational trials [257]. Undertaking one however, would have required considerably 
more expertise in statistics and statistical programming than that we possessed at the 
time.  
6.6.2 Limitations of the cross-sectional study (II) 
While a cross-sectional study was suitable for providing an overview on the prevalent 
disease activity and medical treatment, it did not warrant any causal conclusions as a 
longitudinal study design would have. The data for our study was gathered from six out of 
twenty Finnish hospital districts, which might limit the generalizability of the results to 
the rest of the country. Although the initial protocol called for an equal number of 
participants from each hospital district, this was not achieved. Also, the actual number of 
included patients was not proportional to the total population residing within the 
boundaries of each participating hospital district.  Despite including consecutive patients 
without any additional inclusion criteria into the study, patients with high disease activity 
and hence, more frequent visits to rheumatologists, might be overrepresented. The 
questions on employment status and educational background were misinterpreted or 
omitted by many patients and consequently, we chose not to report the results on these.  
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6.6.3 Limitations of the cohort studies (III and IV) 
Although the ROB-FIN covers an estimated 60% of the biologic treatments in rheumatic 
diseases, the unexposed cDMARD cohort was based only on the records of a single 
hospital district and therefore, the comparisons between the biologics and cDMARD users 
may have limited generalizability [227]. There were differences between the cDMARD 
populations used in the two analyses, however. The study focused on the incidence of 
joint replacement operations (IV) featured follow-up data from a longer period of time 
with limited data on disease activity and co-medication whereas the study on the 
incidence of serious infections and malignancies (III) used data from 2007 onwards based 
electronic reporting with more accurate information on possible confounders. Most of 
the data is gathered alongside daily clinical work where it is not always possible to write 
up information systematically. Missing data was evident in both analyses and had to be 
imputed in order to perform the multivariate analyses. Using multiple imputation 
however, we were able to conduct the analyses on all patients and account for the 
uncertainty caused by the missing data. A large proportion of patients were lost to follow-
up, which may have introduced some bias into our results.  Our data was not accurate 
enough to specify if the biologic treatment was halted shortly prior and after the joint 
replacement surgery. Prior joint replacement operations, serious infections and 
malignancies were used as confounding factors, but the data on joint replacement 
operations and serious infections were only available to us from 1980 and 1998 onwards, 
respectively. Therefore, we may have been able to account for them as confounders only 
partially. Propensity score matching used in the cohort study IV facilitates the analysis of 
the outcome of interest between two groups, but due to exclusion of unmatched 
patients, the results of the remaining participants in either of the treatment arms might 
no longer generalizable to the original population. We did not have information on all 
patients’ co-morbidities, smoking status, educational background, erosive progression in 
weight bearing joints or medication adherence, all of which could potentially confound 
the results. Propensity score matching as well as any other statistical technique besides 
randomization can only account for differences in the measured variables between the 
treatment groups and ignores or even worsens the balance in unmeasured ones. 
The data on infections were retrieved from hospital records, which only represent the 
most severe cases of infections. Serious infection is often in practice defined as one 
requiring hospitalization, whereas mild to moderate infections can usually be treated in 
the outpatient setting. While some infections such as sepsis are always likely to lead to 
hospitalization and the results might therefore represent their true incidence, the same 
cannot be said from bronchitis for example, which is usually treated in community health 
centers by general practitioners. 
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Lag-time in the cohort study on serious infections and malignancies (III) was longer 
compared to that used by some others [121,252]. This was in part motivated due to 
instructed data reporting interval of six months for ROB-FIN and the limitation of us not 
being able to define the medication period more accurately than as the time between 
two visits while on drug. Lag-time was not used in the cohort study on joint replacement 
operations (IV), which could have led to omission of operations taking place shortly after 
the biologic treatment is discontinued or the patient is lost to follow-up. 
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7 CONCLUSIONS  
In the present study we sought to improve the knowledge on the efficacy, long-term 
outcomes and safety of biologic drugs in comparison to synthetic DMARDs.  
I: Our results disclosed few differences between individual TNF-inhibitors regarding 
efficacy and safety based on the information available from randomized clinical trials. 
TNF-inhibitors are more efficacious when used in conjunction with methotrexate 
compared to biologic monotherapy. Our meta-analysis did not identify an increased risk 
for serious infections among biologics users compared to patients on synthetic DMARDs.  
II: The cross sectional review of patients with RA revealed that >50% of patients were in 
DAS28-remission and 70% had low disease activity. Comparison to previous studies 
revealed a possible reduction in disease activity of prevalent RA. Of the included 890 
patients, 21% and 91% were using biologic and synthetic DMARDs, respectively. 
III: There were no statistically significant differences in the incidence of infections 
requiring hospitalization and malignancies between the users of cDMARDs, infliximab, 
etanercept, adalimumab or rituximab. However, it is possible that the present study was 
statistically underpowered. The study population covers a major proportion of Finnish RA 
patients ever exposed to biologic treatment and thus, is highly generalizable inside 
Finland. Generalization outside Finland however, is not recommended due to differences 
in treatment guidelines, population characteristics and comorbidities such as latent 
tuberculosis. 
IV: We tested the assumption that the use of biologic drugs would diminish the need for 
joint replacement surgery in patients with RA. Contrary to our hypothesis the incidence 
rate of operations to joints other than hip was higher among biologics users, may be due 
to unmeasured differences in disease severity and erosive progression. Biologic anti-
rheumatic drugs were not found to be associated with increased risk of infection. Despite 
possibly lower rate of revisions among biologic users, the durability of prostheses was not 
improved compared to DMARD users. It is possible that biologic drugs to a larger extent 
prevented from the need for joint replacement surgery if initiated earlier in the course of 
the disease. More research on the subject is needed and while a randomized controlled 
trial would provide the strongest evidence it may be not feasible considering the long-
time span needed for follow-up. 
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Appendix 1. Search strategy used for (Ovid) Medline. 
Ovid MEDLINE(R), Ovid MEDLINE(R) In-Process (5.2.2010) 
# ID Search term Search results 
1 (rheumatoid adj1 arthritis).mp. 85757 
2 tnf*.mp. 91740 
3 tumo?r necrosis factor*.mp. 105378 
4 antitnf*.mp. 22 
5 anti-tnf*.mp. 4655 
6 antitumo?r necrosis factor*.mp. 233 
7 anti-tumo?r necrosis factor*.mp. 1724 
8 (infliximab* or remicade* or cA2*).mp. 117680 
9 (etanercept* or enbrel* or p75TNFR-Fc*).mp 2430 
10 (adalimumab* or humira* or D2E7*).mp. 1456 
11 (certolizumab* or cimzia* or CDP870*).mp. 173 
12 (golimumab* or simponi* or CNTO-148*).mp. 56 
13 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 238383 
14 random*.mp. 630336 
15 rct*.mp. 8095 
16 ((single* or double* or trebl* or tripl*) adj1 (blind* or mask*)).mp. 141997 
17 placebo*.mp. 135062 
18 (clinical adj trial*).mp. 644131 
19 (meta adj1 analy*).mp. 41768 
20 metaanaly*.mp. 1060 
21 (systematic* adj3 (review* or overview* or litera* or search*)).mp 27972 
22 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 1065142 
23 1 and 13 and 22 1556 
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Appendix 2. Description of the studies included in the systematic review and meta-analysis 
Study and 
additional 
publications 
Intervention (I) and 
control groups (C) 
No of 
pa-
tients 
Disease 
duration 
(years) 
No of 
swollen 
joints 
No  of 
tender 
joints 
HAQ Previous 
MTX use 
MTX dose 
(mg/vk) 
Primary clinical 
outcome 
RCT du-
ration  
  
Abe 200649 I1: 3mg/kg Inf + MTX 
I2: 10mg/kg Inf+ MTX 
C1: MTX + placebo 
Inf at weeks 0, 2 and 6 
49 
51 
47 
 
9,1 
7,1 
7,5 
15,1 
13,2 
13,5 
19 
18,7 
17,8 
n/a 
n/a 
n/a 
Yes 
Yes 
Yes 
7,12 
7,12 
7,42 
 
ACR 20 
14wk 
14 weeks 
Maini 199953 
Lipsky 200051 
Maini 200452 
Smolen 
200556 
I1: Inf 3mg/kg+MTX e8w 
I2: Inf 3mg/kg+MTX e4w 
I3: Inf 10mg/kg+MTX e8w 
I4: Inf 10mg/kg+MTX e4w 
C1: Placebo + MTX 
86 
86 
87 
81 
88 
10 
9 
11 
12 
11 
22 
21 
23 
24 
21 
32 
31 
32 
34 
31 
1.8 
1.7 
1.7 
1.7 
1.7 
Yes 
Yes 
Yes 
Yes 
Yes 
16 
16 
16 
17 
16 
ACR 20 
30wk 
30 weeks 
Quinn 200554 I1: Inf 3mg/kg+MTX 
C1: Placebo + MTX 
Inf at weeks 0, 2 and 6, 
then every 8 weeks 
10 
10 
 
0,62 
0,5 
n/a 
n/a 
n/a 
n/a 
1,3 
1,3 
No 
No 
15 
19 
No clinical 
primary 
endpoints 
12 months 
Schiff 200855 
Bessette 
200750 
Van Vollen-
hoven 200859 
I1: Inf 3mg/kg + MTX 
C1: Placebo + MTX 
Inf at weeks 0, 2 and 6, 
then every 8 weeks 
165 
110 
7,3 
8,4 
20,3 
20,1 
 
31,7 
30,3 
1,7 
1,8 
Yes 
Yes 
16,3 
16,6 
DAS 28 6kk 
(abatacept 
vs. 
infliximab) 
12 months5  
St. Clair 
200458 
Smolen 
200657 
I1: Inf 3mg/kg + MTX 
I2: Inf 10mg/kg + MTX 
C1: Placebo + MTX 
Inf at weeks 0, 2 and 6, 
then every 8 weeks 
359 
363 
282 
0,8 
0,9 
0,9 
21 
22 
22 
32 
33 
34 
1,5 
1,5 
1,5 
No 
No 
No 
15,5 
14,9 
15,1 
ACR-N 54 
wk 
54 weeks 
Bathon 
200061 
Bathon 
200360 
Genovese 
200264
 
I1:  25mg Eta 
C1: MTX + placebo 
Eta twice a week 
207 
217 
 
1 
1 
 
24 
24 
 
31 
30 
n/a 
n/a 
No 
No 
 
19 
ACR-N 0-
6mo 
 
12 months 
Emery 200862 
Emery 201063
 
I1: Eta 50mg + MTX 
C1: MTX + placebo 
Eta once a week 
274 
268 
 
0,733 
0,775 
17,1 
17,6 
25,1 
24,8 
1,7 
1,6 
No 
No 
16,8 
19.6 
(wk 8) 
DAS 
remission 
52wk 
52 weeks 
Keystone 
200466 
I1: Eta 50mg 
I2: Eta 25mg 
C1: Placebo 
Some of the patients on 
MTX  
214 
153 
53 
9 
8,2 
10,8 
19.2 
19.2 
19.2 
263 
29.23 
24.63 
1,4 
1,4 
1,4 
No/yes 
No/yes 
No/yes 
14.3(53%) 
15.0(52%) 
13.8(55%) 
ACR 20 8 
wk 
16 weeks 
Klareskog 
200467 
Kavanaugh 
200865 
Van der 
Heijde 200671 
Van der 
Heijde 200770 
I1: Eta 25mg 
I2: Eta 25mg + MTX 
C1: Placebo + MTX 
Eta twice a week 
223 
231 
228 
6,3 
6,8 
6,8 
23,0 
22,1 
22,6 
35 
34,2 
33,1 
1.7 
1.8 
1.7 
No/yes 
No/yes 
No/yes 
16,9 
17,2 
(wk 8) 
ACR-N wk 
24 
52 weeks 
Lan 200468 I1: Eta 25mg + MTX 
C1: Placebo + MTX 
Eta twice a week 
29 
29 
 
n/a 
n/a 
13,211 
14.451 
14,031 
16.001 
0,99 
1,23 
Yes 
Yes 
12,5-20 
12,5-20 
SJC and TJC  12 weeks 
Moreland 
199969 
I1: Eta 25mg 
C1: Placebo 
Eta twice 2 week 
78 
80 
 
11 
12 
 
25 
25 
33 
35 
1,6 
1,7 
No/yes 
No/yes 
 ACR 20 and 
50 3 and 
6mo 
6 months 
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Weinblatt 
199972 
I1: Eta 25mg + MTX 
C1: Placebo + MTX 
Eta twice a week 
59 
30 
13 
13 
 
204 
174 
284 
284 
1,54 
1,54 
Yes 
Yes 
19 
18 
Endpoints 
not 
specified 
24 weeks 
Breedveld 
200673 
I1:  Ada 40 mg + MTX 
 I2: Ada 40 mg + placebo 
C1: MTX + placebo 
Ada every other week 
274 
268 
257 
0,7 
0,7 
0,8 
21,8 
21,1 
22,1 
31,8 
30,7 
32,3 
1,6 
1,5 
1,5 
No 
No 
No 
0 
16.3 
16.9 
 
ACR 50 
12mo 
 
2 years 
Chen 200974 I1: Ada 40mg + MTX 
C1: MTX + placebo 
Ada every other week 
35 
12 
6,2 
8,3 
21,9 
24,1 
 
32,5 
37,2 
1,7 
1,8 
Yes 
Yes 
10-15 
10-15 
ACR 20 
12wk 
12 weeks 
Keystone 
200477 
Jamal 200975 
Keystone 
200376 
I1: Ada 40mg + MTX 
C1: Placebo + MTX 
Ada every other week 
207 
200 
 
11 
10,9 
19,3 
19,0 
27,3 
28,1 
1,45 
1,48 
 
Yes 
Yes 
16.7 
16.7 
ACR 20 wk 
24 
HAQ wk 54 
52 weeks 
Kim 200778 I1: Ada 40mg + MTX  
C1: Placebo + MTX 
Ada every other week 
65 
63 
6,8 
6,9 
12,2 
12,8 
 
19,2 
20,3 
1,4 
1,3 
Yes 
Yes 
16,62 
16,32 
ACR 20 wk 
24 
24 weeks 
Miyasaka 
200879 
I1: Ada 40mg 
I2: Ada 80mg 
C1: Placebo 
Ada every other week 
91 
87 
87 
9,9 
9,5 
8,4 
19,1 
20,8 
19,3 
24,4 
24,9 
23,7 
1,64 
1,77 
1,39 
No/yes 
No/yes 
No/yes 
 ACR 20 
24wk 
24 weeks 
Van de Putte 
200380 
I1: Ada 40mg 
I2: Ada 80mg 
C1: Placebo 
Ada every other week 
70 
72 
70 
10 
10,1 
9,4 
18,7 
19,6 
19,8 
31,0 
32,5 
30,9 
1,74 
1,66 
1,63 
No/yes 
No/yes 
No/yes 
 ACR 20 
12wk 
12 weeks 
Van de Putte 
200481 
I1: Ada 40mg eow 
I2: Ada 40mg weekly 
C1: Placebo 
 
113 
103 
110 
 
10,6 
11,9 
11,6 
20,5 
19,3 
19,8 
33,7 
33,8 
35,5 
1,83 
1,84 
1,88 
No/yes 
No/yes 
No/yes 
 ACR 20 26 weeks 
Weinblatt 
200382 
I1: Ada 40mg + MTX 
I2: Ada 80mg + MTX 
C1: Placebo + MTX 
Ada every other week 
67 
73 
62 
12,2 
12,8 
11,1 
17,3 
17,0 
16,9 
 
28,0 
30,3 
28,7 
1,55 
1,55 
1,64 
Yes 
Yes 
Yes 
16,4 
17,2 
16,5 
ACR 20 
24wk 
24 weeks 
Emery 200983 I1: Gol 100mg+placebo 
I2: Gol 50mg+MTX 
I3: Gol 100mg+MTX 
C1: MTX + placebo 
Gol every 4 weeks 
159 
159 
159 
160 
4.1 
3.5 
3.6 
2.9 
 
12 
13 
14 
11 
24,5 
26 
26 
25,5 
1,7 
1,5 
1,6 
1,5 
No 
No 
No 
No 
 
19,2 
19,1 
19,1 
(wk 23) 
ACR 50 
24wk 
52 weeks 
Kay 200884 I1: Gol 50mg+MTX (eow) 
I2: Gol 50mg+MTX (e4w) 
I3: Gol 100mg+MTX 
(eow) 
I4: Gol 100mg+MTX 
(e4w) 
C1: MTX + placebo 
35 
34 
34 
34 
35 
8,2 
8,2 
6,3 
9,0 
5,6 
14 
14 
20 
14 
13 
28 
28 
32 
22 
22 
 
1,7 
1,6 
1,8 
1,3 
1,3 
Yes 
Yes 
Yes 
Yes 
Yes 
≥10 
≥10 
≥10 
≥10 
≥10 
ACR 20 
16wk 
52 weeks 
Keystone 
200985 
I1: Gol 100mg + placebo 
I2: Gol 50mg + MTX 
I3: Gol 100mg + MTX 
C1: MTX + placebo 
Gol every 4 weeks 
133 
89 
89 
133 
5,9 
4,5 
6,7 
6,5 
11 
13 
12 
12 
22 
26 
23 
21 
1,38 
1,38 
1,38 
1,25 
Yes 
Yes 
Yes 
Yes 
15 
15 
15 
15 
ACR 20 wk 
14 
52 weeks 
Fleischmann 
200986  
I1: Cer 400mg  
C1: Placebo 
Cer every 4 weeks 
111 
109 
 
8,7 
10,4 
21,2 
19,9 
 
29,6 
28,3 
1,4 
1,6 
No/yes 
No/yes 
 ACR 20 
24wk 
24 weeks 
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Keystone 
200887 
 
I1: Cer 200mg + MTX 
I2: Cer 400mg + MTX 
C1: MTX + placebo 
Cer every 2 weeks 
393 
390 
199 
6,1 
6,2 
6,2 
 
21,7 
21,5 
21,2 
30,8 
31,1 
29,8 
1,7 
1,7 
1,7 
Yes 
Yes 
Yes 
13,62 
13,62 
13,42 
ACR 20 wk 
24 
52 weeks 
Smolen 
200988 
I1: Cer 200mg + MTX 
I2: Cer 400mg + MTX 
C1: Placebo + MTX 
Cer every other week 
246 
246 
127 
6,1 
6,5 
5,6 
20,5 
21,0 
21,9 
30,1 
30,0 
30,4 
1,6 
1,6 
1,6 
Yes 
Yes 
Yes 
12,52 
12,62 
12,22 
ACR 20 
24wk 
24 weeks 
1 = Evaluation based on 28 joints                                                         Ada = Adalimumab                      MTX = methotrexate 
2 = Baseline data                                                                                     Cer = Certolizumab pegol 
3 = Evaluation based on 71 joints                                                        Eta = Etanercept 
4 = Values in median                                                                              Gol = Golimumab 
5= placebo switched to active medication at 6 months                  Inf = Iinfliximab 
110 
 
 
 
 
 
 
 
 
 
 
ORIGINAL PUBLICATIONS 
